{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch\n",
    "import os\n",
    "import pandas as pd\n",
    "import matchzoo as mz\n",
    "import numpy as np\n",
    "from sklearn.model_selection import train_test_split"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3\n",
      "(3,)\n",
      "<class 'int'>\n",
      "Classification Task with 3 classes\n"
     ]
    }
   ],
   "source": [
    "TYPE = 'classification'\n",
    "\n",
    "classification_task = mz.tasks.Classification(num_classes=3)\n",
    "classification_task.metrics = ['acc']\n",
    "print(classification_task.num_classes)\n",
    "print(classification_task.output_shape)\n",
    "print(classification_task.output_dtype)\n",
    "print(classification_task)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data Pack Sample"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id_left</th>\n",
       "      <th>text_left</th>\n",
       "      <th>id_right</th>\n",
       "      <th>text_right</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>L-0</td>\n",
       "      <td>A</td>\n",
       "      <td>R-0</td>\n",
       "      <td>a</td>\n",
       "      <td>-1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>L-1</td>\n",
       "      <td>B</td>\n",
       "      <td>R-0</td>\n",
       "      <td>a</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>L-1</td>\n",
       "      <td>B</td>\n",
       "      <td>R-1</td>\n",
       "      <td>c</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>L-2</td>\n",
       "      <td>C</td>\n",
       "      <td>R-2</td>\n",
       "      <td>b</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>L-3</td>\n",
       "      <td>D</td>\n",
       "      <td>R-3</td>\n",
       "      <td>d</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  id_left text_left id_right text_right  label\n",
       "0     L-0         A      R-0          a     -1\n",
       "1     L-1         B      R-0          a      1\n",
       "2     L-1         B      R-1          c      0\n",
       "3     L-2         C      R-2          b      0\n",
       "4     L-3         D      R-3          d      1"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# pack\n",
    "df = pd.DataFrame(data={'text_left': list('ABBCD'),\n",
    "                       'text_right': list('aacbd'),\n",
    "                       'label': [-1, 1, 0, 0, 1]})\n",
    "mz.pack(df, task=TYPE).frame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# data_pack\n",
    "left = [\n",
    "    ['artid1', 'A1'],\n",
    "    ['artid2', 'A2'],\n",
    "    ['artid3', 'A3']\n",
    "]\n",
    "right = [\n",
    "    ['hypoid1', 'prompt1'],\n",
    "    ['hypoid2', 'prompt2'],\n",
    "    ['hypoid3', 'prompt3']\n",
    "]\n",
    "relation = [\n",
    "    ['artid1', 'hypoid1', -1],\n",
    "    ['artid1', 'hypoid3', 1],\n",
    "    ['artid2', 'hypoid2', 0],\n",
    "    ['artid3', 'hypoid3', 1]\n",
    "]\n",
    "\n",
    "relation_df = pd.DataFrame(relation)\n",
    "# relation_df\n",
    "left = pd.DataFrame(left)\n",
    "right = pd.DataFrame(right)\n",
    "dp = mz.DataPack(\n",
    "    relation=relation_df,\n",
    "    left=left,\n",
    "    right=right\n",
    ")\n",
    "# print(len(dp))\n",
    "# print(type(dp.frame))\n",
    "# frame_slice = dp.frame[0:5]\n",
    "# type(frame_slice)\n",
    "# list(frame_slice.columns)\n",
    "# full_frame = dp.frame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "matchzoo.data_pack.data_pack.DataPack"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_pack = mz.datasets.toy.load_data(stage='train')\n",
    "type(data_pack)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Prepare input data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "UserID              int64\n",
      "PromptID            int64\n",
      "PMCID               int64\n",
      "Valid Label          bool\n",
      "Valid Reasoning      bool\n",
      "Label              object\n",
      "Annotations        object\n",
      "Label Code          int64\n",
      "In Abstract          bool\n",
      "Evidence Start      int64\n",
      "Evidence End        int64\n",
      "dtype: object\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>UserID</th>\n",
       "      <th>PromptID</th>\n",
       "      <th>PMCID</th>\n",
       "      <th>Valid Label</th>\n",
       "      <th>Valid Reasoning</th>\n",
       "      <th>Label</th>\n",
       "      <th>Annotations</th>\n",
       "      <th>Label Code</th>\n",
       "      <th>In Abstract</th>\n",
       "      <th>Evidence Start</th>\n",
       "      <th>Evidence End</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>13994</th>\n",
       "      <td>0</td>\n",
       "      <td>7902</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>significantly increased</td>\n",
       "      <td>Mivacurium 250 μg/kg produced a maximal T bloc...</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1280</td>\n",
       "      <td>1395</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14000</th>\n",
       "      <td>3</td>\n",
       "      <td>7904</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>no significant difference</td>\n",
       "      <td>Heart rate was similar between doses</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>1452</td>\n",
       "      <td>1488</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12483</th>\n",
       "      <td>0</td>\n",
       "      <td>7905</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>significantly decreased</td>\n",
       "      <td>while both AUC-SBP and AUC-DBP were significan...</td>\n",
       "      <td>-1</td>\n",
       "      <td>False</td>\n",
       "      <td>16737</td>\n",
       "      <td>16836</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12484</th>\n",
       "      <td>1</td>\n",
       "      <td>7905</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>significantly decreased</td>\n",
       "      <td>In relation to the cardiovascular response, th...</td>\n",
       "      <td>-1</td>\n",
       "      <td>False</td>\n",
       "      <td>16641</td>\n",
       "      <td>16836</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13999</th>\n",
       "      <td>0</td>\n",
       "      <td>7904</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>no significant difference</td>\n",
       "      <td>In relation to the cardiovascular response, th...</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "      <td>16641</td>\n",
       "      <td>16736</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13998</th>\n",
       "      <td>3</td>\n",
       "      <td>7903</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>no significant difference</td>\n",
       "      <td>Spontaneous recovery times were similar in bot...</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>1396</td>\n",
       "      <td>1450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13997</th>\n",
       "      <td>0</td>\n",
       "      <td>7903</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>no significant difference</td>\n",
       "      <td>The times to OA and to spontaneous recovery of...</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "      <td>14755</td>\n",
       "      <td>15079</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13995</th>\n",
       "      <td>3</td>\n",
       "      <td>7902</td>\n",
       "      <td>60007</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>significantly increased</td>\n",
       "      <td>Mivacurium 250 μg/kg produced a maximal T bloc...</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1280</td>\n",
       "      <td>1395</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2855</th>\n",
       "      <td>0</td>\n",
       "      <td>1806</td>\n",
       "      <td>111193</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>no significant difference</td>\n",
       "      <td>The amount of blood transfusion was identical ...</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>1418</td>\n",
       "      <td>1578</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2334</th>\n",
       "      <td>0</td>\n",
       "      <td>1808</td>\n",
       "      <td>111193</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>no significant difference</td>\n",
       "      <td>There was no difference in time spent in hospi...</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "      <td>14701</td>\n",
       "      <td>14770</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       UserID  PromptID   PMCID  Valid Label  Valid Reasoning  \\\n",
       "13994       0      7902   60007         True             True   \n",
       "14000       3      7904   60007         True             True   \n",
       "12483       0      7905   60007         True             True   \n",
       "12484       1      7905   60007         True             True   \n",
       "13999       0      7904   60007         True             True   \n",
       "13998       3      7903   60007         True             True   \n",
       "13997       0      7903   60007         True             True   \n",
       "13995       3      7902   60007         True             True   \n",
       "2855        0      1806  111193         True             True   \n",
       "2334        0      1808  111193         True             True   \n",
       "\n",
       "                           Label  \\\n",
       "13994    significantly increased   \n",
       "14000  no significant difference   \n",
       "12483    significantly decreased   \n",
       "12484    significantly decreased   \n",
       "13999  no significant difference   \n",
       "13998  no significant difference   \n",
       "13997  no significant difference   \n",
       "13995    significantly increased   \n",
       "2855   no significant difference   \n",
       "2334   no significant difference   \n",
       "\n",
       "                                             Annotations  Label Code  \\\n",
       "13994  Mivacurium 250 μg/kg produced a maximal T bloc...           1   \n",
       "14000               Heart rate was similar between doses           0   \n",
       "12483  while both AUC-SBP and AUC-DBP were significan...          -1   \n",
       "12484  In relation to the cardiovascular response, th...          -1   \n",
       "13999  In relation to the cardiovascular response, th...           0   \n",
       "13998  Spontaneous recovery times were similar in bot...           0   \n",
       "13997  The times to OA and to spontaneous recovery of...           0   \n",
       "13995  Mivacurium 250 μg/kg produced a maximal T bloc...           1   \n",
       "2855   The amount of blood transfusion was identical ...           0   \n",
       "2334   There was no difference in time spent in hospi...           0   \n",
       "\n",
       "       In Abstract  Evidence Start  Evidence End  \n",
       "13994         True            1280          1395  \n",
       "14000         True            1452          1488  \n",
       "12483        False           16737         16836  \n",
       "12484        False           16641         16836  \n",
       "13999        False           16641         16736  \n",
       "13998         True            1396          1450  \n",
       "13997        False           14755         15079  \n",
       "13995         True            1280          1395  \n",
       "2855          True            1418          1578  \n",
       "2334         False           14701         14770  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "annot = pd.read_csv('./annotations/annotations_merged.csv')\n",
    "print(annot.dtypes)\n",
    "annot.sort_values('PMCID').head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "\"\"\"Process txt file for Articles input\"\"\"\n",
    "TXT_PATH = './annotations/txt_files/'\n",
    "TAR_PATH = './annotations/processed_txt_files/'\n",
    "look_up = {}\n",
    "\n",
    "if not os.path.exists(TAR_PATH):\n",
    "    os.mkdir(TAR_PATH)\n",
    "# else: os.removedirs(TAR_PATH)\n",
    "for file in os.listdir(TXT_PATH):\n",
    "    fname = file[3:]\n",
    "    look_up[int(file[3:-4])] = fname\n",
    "    with open(TXT_PATH+file, 'r', encoding='utf-8') as f, open(TAR_PATH+fname, 'w', encoding='utf-8') as t:\n",
    "        for line in f.readlines():\n",
    "            t.write(line.strip())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "\"\"\"Articles Map\"\"\"\n",
    "left_articles = []\n",
    "for file in os.listdir(TAR_PATH):\n",
    "    with open(TAR_PATH+file, 'r', encoding='utf-8') as f:\n",
    "        left_articles.append([int(file[:-4]), f.readlines()[0]])\n",
    "# print(left_articles[0:5])\n",
    "\n",
    "\"\"\"Prompts Map\"\"\"\n",
    "right_prompts = [list(pair) for pair in zip(annot['PromptID'].values, annot['Annotations'].values)]\n",
    "print(right_prompts[0:5])\n",
    "\n",
    "\"\"\"Articles <-> Prompts Map\"\"\"\n",
    "article_prompt_relations = [list(triplet) for triplet in zip(annot['PMCID'].values, \n",
    "                                                             annot['PromptID'].values, \n",
    "                                                             annot['Label Code'].values)]\n",
    "print(article_prompt_relations[0:5])\n",
    "\n",
    "\"\"\"Create Data-pack\"\"\"\n",
    "left = pd.DataFrame(left_articles, columns=['id_left', 'text_left'])\n",
    "right = pd.DataFrame(right_prompts, columns=['id_right', 'text_right'])\n",
    "relation = pd.DataFrame(article_prompt_relations, columns=['id_left', 'id_right', 'label'])\n",
    "dp = mz.DataPack(\n",
    "    relation = relation,\n",
    "    left = left,\n",
    "    right = right\n",
    ")\n",
    "\n",
    "# print(left)\n",
    "# print(len(dp))\n",
    "# print(type(dp.frame))\n",
    "# frame = dp.frame\n",
    "# print(list(frame().columns))\n",
    "# # frame_slice = dp.frame[0:5]\n",
    "# # type(frame_slice)\n",
    "# # list(frame_slice.columns)\n",
    "# full_frame = dp.frame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"TITLE: Influence of dextran-70 on systemic inflammatory response and myocardial ischaemia-reperfusion following cardiac operationsABSTRACT.INTRODUCTION:Experimental studies have demonstrated that dextran-70 reduces the leukocyte–endothelium interaction, but clinical evidence is still lacking. Our objective was to justify the anti-inflammatory effect of dextran-70 following cardiac operations.ABSTRACT.METHODS:Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20). The plasma concentration of procalcitonin, C-reactive protein, IL 6, IL 6r, IL 8, IL 10, soluble endothelial leukocyte adhesion molecule-1, soluble intercellular adhesion molecule-1, cardiac troponin-I and various haemodynamic parameters were measured in the perioperative period. Multivariate methods were used for statistical analysis.ABSTRACT.RESULTS:In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found. There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups. Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.ABSTRACT.CONCLUSION:Our investigation demonstrated that the use of dextran-70 reduces the systemic inflammatory response and cardiac troponin-I release following cardiac operation.ABSTRACT.TRIAL REGISTRATION NUMBER:ISRCTN38289094.BODY.INTRODUCTION:Cardiac surgery on cardiopulmonary bypass (CPB) results in a complex immune response characterized by the activation of all inflammatory pathways and strongly related to increased postoperative morbidity and mortality. The immune activation due to systemic inflammatory response syndrome exposes the patient to postoperative wound healing complications and to the development of infections [1,2].  Increased levels of the proinflammatory cytokines IL-6 and IL-8 play a major role in the pathogenesis of ischaemia-reperfusion injury [3] and multiple organ dysfunction syndrome [4]. IL-8 is a crucial chemokine, which attracts and activates polymorphonuclear leukocytes (PMNs) as well as T lymphocytes, and controls their migration. Tissue penetration, free radical production, and granulocyte elastase synthesis and release are also increased in PMNs [4]. Serum procalcitonin is a sensitive marker for the early detection of systemic inflammatory response syndrome [5]. Procalcitonin levels above 2 ng/ml are predictive for postoperative complications after cardiac operations [6]. Owing to inflammation, soluble adhesion molecules are shed into the circulation and their concentration correlates with the magnitude of endothelial activation and injury [1,7].  Several investigations have demonstrated that artificial colloids modulate the inflammatory response. Animal experiments have confirmed that dextran decreases the endothelial adhesion of PMNs in the postischaemic phase independently of the haemodilution [8]. Among trauma patients, dextran administration counteracts monocyte dysfunction and the related imbalance between coagulation and fibrinolysis [9]. Hypertonic saline dextran suppressed myocardial TNF-α, IL-1β and IL-6 secretion after an initial burn injury in an animal study, improving ventricular performance after subsequent septic challenge [10]. Experimental and clinical studies have justified the beneficial effects of dextran in the prevention of acute respiratory distress syndrome following trauma and sepsis [11], radiation injury [12], pancreatitis [13] and lower limb reperfusion injury [14].  It has been reported that hydroxyethyl starches (HES) reduce capillary leakage [15], leading to the concept of 'plugging the leaks' in various diseases, including sepsis and burns [16]. In a polymicrobial sepsis model, HES inhibited the inflammatory cytokine response, neutrophil infiltration and expression of intercellular adhesion molecule-1 (ICAM-1) mRNA [17]. Other anti-inflammatory manifestations of low-molecular-weight HES include impaired neutrophil respiratory burst and reduced neutrophil chemotaxis [18]. Administration of HES was associated with reduced markers of inflammation and endothelial activation in sepsis [19] and in patients undergoing major abdominal surgery [20].  Without any evidence of modulating the inflammatory response, gelatin infusion has been considered pharmacologically inert [21]. This assumption was confirmed in an experimentally induced acute lung injury model, where the inflammatory response (TNF-α) and oxidative stress were not affected by gelatin [22]. A recently published investigation has also indicated that NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity were not affected by modified fluid gelatin in a polymicrobial sepsis model [17] – whereas, like other artificial colloids, gelatin impairs firm leukocyte adhesion to the endothelium in vitro [23], and applied in the priming fluid gelatin reduces the contact activation of complement cascades by binding to fragment Ba [24]. Nevertheless an increased TNF-α release was demonstrated after the incubation of blood with gelatin in vitro [25], but in vivo investigation has revealed that gelatin does not alter PMN function [26].  Despite numerous studies having been published concerning the influence of colloids on inflammation, only few comparative studies exist. Reducing the endothelial adhesion of PMNs, dextran was reported to be more potent than HES in leukocyte-related reperfusion injury, and in contrast to HES the anti-inflammatory effect of dextran developed even in nondilutional microdose administration [8].  On the basis of experimental data it may be hypothesized that dextran attenuates the inflammatory response following cardiac surgery. There are, however, no exact clinical data in the literature that would support the anti-inflammatory effect of dextran following cardiac surgery. Our objective was the investigation of the effects of dextran-70 compared with gelatin as a control, on the levels of serum procalcitonin, on the inflammatory cytokine response, the markers of endothelial damage, myocardial ischaemia-reperfusion injury and haemodynamics after CPB. Our hypothesis was that administration of dextran reduces the level of inflammatory mediators and cardiac troponin-I (cTr-I) at the most important timepoints.BODY.MATERIALS AND METHODS:With permission from the ethical committee of the hospital, 40 patients undergoing elective first-time CPB – 32 patients undergoing coronary artery revascularization (coronary artery bypass grafting (CABG)), eight patients undergoing aortic valve replacement (AVR) – were involved in this prospective, randomized, double-blind study after individual consent was obtained. The setting of the study was single institutional. Two experienced anaesthesiologists and two experienced surgeons were involved in the study. Exclusion criteria were as follows: 'redo' operation, hepatic disease, renal dysfunction, immunologic disease, steroid treatment, intake of aspirin or other cyclooxygenase inhibitor within 7 days prior to surgery, or known allergy to volume expanders used in the study. None of the patients received volatile anaesthetics, steroids or aprotinin and haemofiltration was not used either. No shed mediastinal blood was retransfused during the postoperative period.  Two groups were formed following computerized randomization. Twenty patients (CABG, 17 patients; AVR, three patients) were given dextran-70 (6%; average molecular weight 70,000 Da) infusion (Macrodex; Pharmalink, Inc., Upplands Väsby, Sweden) (group A), while in the control group 20 patients (CABG, 15 patients; AVR, five patients) were given oxypolygelatin (5.5%; average molecular weight 30,000 Da) infusion (Gelifundol; Biotest Pharma, Inc., Dreieich, Germany) (group B). Following the induction of anaesthesia, artificial colloid was administered using infusion pumps (Model 591; IVAC, Inc., San Diego, CA, USA). After the application of hapten inhibition by 20 ml dextran-1 (Promit; Fresenius Kabi, Inc., Norge AS, Norway), dextran-70 infusion was used at the dose of 7.5 ml/kg for 30 minutes before CPB, and at a dose of 12.5 ml/kg for 14 hours following the cessation of CPB. Gelatin was infused by the same body-weight-based volume as dextran. The indication of the colloid administration was volume substitution. Depending on the actual haemodynamic and volume status, crystalloid infusion was administered together with a fixed dose of colloid.  Anaesthesia was carried out by a standardized total intravenous method. Premedication was achieved with midazolam. For the induction of anaesthesia, midazolam, propofol in a target controlled infusion perfusion device using DiprifusorTM (Alaris Medical Systems, Hampshire, UK), alfentanil and pipecuronium were used, while propofol (target controlled infusion) and alfentanil were given to maintain anaesthesia. Anticoagulation was maintained with heparin (initial value 300 IU/kg) to keep the activated clotting time longer than 400 seconds. Protamine was administered in a 1:1 ratio based on the initial heparin bolus (necessary to achieve the target activated clotting time). Cardiopulmonary bypass was carried out in normothermia, with the use of a roller pump (Cobe Cardiovascular, Inc., Arvada, Colorado USA), with pulsatile flow rate of 2.4 l/min/m2 and a membrane oxygenator (AffinityTM NT 541; Medtronic, Inc., Minneapolis, MN, USA). Antegrade, cold, crystalloid cardioplegia (modified Bretschneider solution) injected into the aortic root was used for myocardial protection. The Pulsion PiCCOTM (Pulsion Medical Systems, Inc., München, Germany) device was used for haemodynamic monitoring.  Packed red blood cell administration was applied when the haemoglobin level was less then 90 g/l, or during CPB when haemoglobin was below 70 g/l. Postoperative complications were defined as follows: cardiovascular complication (low cardiac output with cardiac index <2.2 l/min/m2 after volume infusion, requiring the use of positive inotrop agents and/or intraaortic balloon pump); perioperative myocardial infarction with typical electrocardiogram changes and creatine kinase MB >75 U/ml (three times the upper limit of the reference range); acute lung injury (prolonged ventilation, PaO2/FiO2 ratio <200); acute renal failure (serum creatinine >230 μmol/l); neurologic complications (stroke, ischaemic insults); gastrointestinal complications (ischaemia, bleeding); and infections.  Arterial blood samples were taken from the indwelling femoral artery cannula at the following time intervals: t1, before anaesthesia; t2, 10 minutes after CPB; t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; and t6, 44 hours after CPB. At the same timepoints, the following haemodynamic parameters were registered: heart rate, arterial blood pressure, cardiac index, stroke volume index, stroke volume variation, systemic vascular resistance index (SVRI), intrathoracic blood volume index, and extravascular lung water index. The haematocrit (packed cell volume), haemoglobin and blood cell count were measured at all time intervals. Determination of the plasma concentration of inflammatory mediators – interleukins (IL-6, IL-6r, IL-8, IL-10) and soluble adhesion molecules (soluble endothelial leukocyte adhesion molecule-1 (sELAM-1), soluble ICAM-1) – was carried out by ELISA (DIACLONE ResearchTM, Besançon, France) complying with the technologic regulations of the manufacturer. Blood samples were centrifuged with a cooled centrifuge at 1,000 × g for 15 minutes. Centrifuged plasma was stored at -86°C.  Three plasma samples were analysed for cytokine and soluble adhesion molecule levels with the sampling timepoints based on the kinetics of the single mediators according to the data in the literature. In each case the first measurement point was the preoperative control value, the second was the expected maximal value of the given mediator after cardiac surgery, while the third measurement point was the value corresponding to the dropoff phase [1,7]. The t1, t3 and t4 samples were analysed for IL-6 and IL-6r, while for IL-8 and IL-10 determinations the t1, t2, and t3 samples were used. Monitoring of the adhesion molecules was done as follows: sELAM-1 at the t1, t4 and t5 timepoints, and soluble ICAM-1 as the t1, t5 and t6 samples. The average of the duplicated ELISA test results was corrected using the following equation: corrected concentration = noncorrected concentration × actual plasma fraction/plasma fraction of the t1 sample. Procalcitonin was measured using an immunoluminometric assay (reference range 0–0.5 ng/ml; LUMItestTM; BRAHMS GmbH, Berlin, Germany). For the measurement of serum C-reactive protein the immune turbidimetric method was used (reference range 0–10 mg/l; DIALABTM, Vienna, Austria). cTr-I was measured by a two-site immunoluminometric assay (reference range 0–0.03 ng/ml; LIAISONTM Troponin I; DiaSorin S.p.A, Saluggia, Italy). For procalcitonin measurements we used the t1 and t5 blood samples, while for C-reactive protein the t1, t5 and t6 samples were used, and for cTr-I the t1, t4, t5 and t6 samplings were used.BODY.MATERIALS AND METHODS.STATISTICAL ANALYSIS:Statistical analysis was performed by SPSS for Windows 9.0 software (SPSS Inc., Chicago, Illinois, USA). After obtaining the results for 22 patients a midterm analysis was performed to calculate the necessary total sample size – Altman's nomogram [27] was used after calculating the standardized difference of the inflammatory mediators, setting the statistical power at 80% and choosing a 5% significance level. In the case of IL-8, IL-10, ICAM-1 and procalcitonin, the standardized difference and the necessary sample size were (0.924) 36, (0.886) 39, (1.326) 19 and (1.041) 29, respectively. According to the midterm analysis the sample size was determined to be 40 patients.  For the comparison of the basic data, the chi-squared test and Student's t test were used. We checked the parameters for normal distribution by the Kolmogorov–Smirnov test. If the result proved significant, the nonparametric test was used consecutively. Among inflammatory markers and cTr-I, nonparametric methods were used (Kruskal–Wallis test, Friedman test); and for haemodynamic parameters the general linear model repeated-measurement analysis (analysis of variance) with Bonferroni adjustment for multiple comparison was used for the analysis of the intraindividual and interindividual differences. Any difference was regarded statistically significant if p < 0.05. The results are displayed in the form of the mean ± standard deviation, as the median (range), or as a box-plot where the median, 25–75% and 2.5–97.5% percentile ranges are depicted.BODY.RESULTS:Past medical and perioperative data of the two groups are presented in Table 1. No operative mortality, low cardiac output, lung injury, renal failure, neurological complications, gastrointestinal complications, surgical intraoperative problems or wound healing problems occurred among the patients involved in the study. Myocardial infarction had developed in three cases, one case in group A and two cases in group B. Positive inotrope drug was not applied after the operation, and no differences were found in the frequency of vasodilator therapy (p = 0.584) or β-blocker therapy (p = 0.333) between the groups. The total postoperative mediastinal and pleural drainage proved to be higher in group A. Nevertheless, the amount of the transfused red blood cell units did not differ between the two groups. There was also no significant difference between the preoperative and the 44-hour postoperative haematocrit values, which indicates that the red blood cell loss was approximately the same in both groups.   Table 1 Anamnestic and perioperative data Group A Group B p  value a Age (years) 61.1 ± 6.5 62.5 ± 7.6 0.535 Gender (male/female) 13/7 14/6 0.736 Body mass index (kg/m 2 ) 28.7 ± 3.9 28.9 ± 3.8 0.821 Hypertension (%) 47.2 52.8 0.292 Diabetes mellitus (type I/type II/impaired glucose tolerance) (%) 2/4/1 2/3/1 0.733 Preoperative ejection fraction (%) 55.6 ± 12.6 56.1 ± 9.7 0.906 EuroScore (log) (%) 2.5 ± 1.2 2.9 ± 1.4 0.405 Amount of plasma substitute (ml) 1626 ± 212 1606 ± 205 0.725 Amount of crystalloids (ml) 4172 ± 660 4107 ± 665 0.765 Number of anastomoses (coronary artery bypass graft) 3.5 ± 1.0 3.5 ± 0.9 0.991 Aortic Xclamp (min) 53 ± 13.8 59 ± 18.1 0.403 Cardiac surgery on cardiopulmonary bypass duration (min) 83 ± 23.7 90 ± 29.3 0.401 Operation time (min) 249 ± 64.5 258 ± 61.7 0.634 Minimum rectal temperature (°C) 34.8 ± 0.6 35.0 ± 0.5 0.274 Preoperative packed cell volume 0.40 ± 0.034 0.39 ± 0.040 0.723 Postoperative 44 hours packed cell volume 0.30 ± 0.035 0.30 ± 0.035 0.623 Postoperative drainage (44 hours, ml) 818 ± 286 588 ± 179 0.005 Red blood cell transfusion (U) 1.8 ± 1.3 1.6 ± 1.2 0.548 Extubation time (hours) 9.2 ± 4.1 9.3 ± 4.6 0.894 Intensive care unit stay (hours) 54 ± 23 47 ± 6 0.209 Hospital stay (days) 9.9 ± 2.4 8.9 ± 1.3 0.114 Data presented as the mean ± standard deviation.  a Chi-squared test or Student's  t  test.   The peak level of procalcitonin was lower in group A (Figure 1.). The procalcitonin level was below 2 ng/ml for all of the patients in group A, but it increased in 40% of the patients in group B with a peak level higher than 2 ng/ml (P = 0.001). IL-8 level elevation was moderate in group A in contrast to the increase experienced in the control group, which is a well-known characteristic of CPB. The between-group difference in IL-8 was significant after CPB (Figure 2). The same kinetics were found for IL-10 (Table 2). The preoperative concentration of sELAM-1 was higher in group A, and did not increase any further, in contrast to the control group that started at a low preoperative value and subsequently rose significantly (Table 2). The level of soluble ICAM-1 did not show any increase in group A. On the contrary, there was a significant and characteristic increase in the control group. The between-group differences for soluble ICAM-1 were significant after CPB (Figure 3). No significant difference was found in C-reactive protein, IL-6 or IL6r between the groups. The cTr-I levels were lower in group A, especially at the t5 timepoint (Table 2).  Table 2 Results of the inflammatory mediators and cardiac troponin I t1 t2 t3 t4 t5 t6 p C-reactive protein (mg/l) \\u2003Group A 3.7 (1.0–22.6) 79.9 (50.0–131.7) 112.0 (61.1–177.6) <0.001 † \\u2003Group B 2.6 (0.6–10.5) 87.6 (52.4–143.0) 131.0 (71.0–228.0) <0.001 † p  = 0.068* p  = 0.092* p  = 0.168* IL-6 (pg/ml) \\u2003Group A 1.6 (0.4–21.8) 95.0 (13.6–405.1) 46.3 (16.1–149.5) <0.001 † \\u2003Group B 2.0 (0.4–60.6) 130.5 (21.7–353.8) 49.2 (14.8–214.5) <0.001 † p  = 0.107* p  = 0.829* p  = 0.482* IL-6r (ng/ml) \\u2003Group A 43.6 (1.7–125.0) 47.4 (0.7–109.5) 56.2 (25.2–226.3) 0.949 † \\u2003Group B 40.7 (15.6–94.6) 42.4 (22.2–100.5) 50.2 (13.2–104.9) 0.861 † p  = 0.607* p  = 0.914* p  = 0.304* IL-10 (pg/ml) \\u2003Group A 1.9 (0.2–24.0) 47.2 (2.3–476.6) 7.2 (1.3–90.9) <0.001 † \\u2003Group B 2.6 (0.8–9.7) 209.7 (16.3–814.3) 56.1 (3.6–225.1) <0.001 † p  = 0.136* p  = 0.001* p  = 0.001* Soluble endothelial leukocyte adhesion molecule-1 (ng/ml) \\u2003Group A 88.6 (49.8–194.5) 88.5 (14.4–189.6) 72.7 (8.9–163.1) 0.058 † \\u2003Group B 49.0 (18.3–144.1) 130.7 (33.0–360.7) 72.6 (16.7–224.7) <0.001 † p  < 0.001* p  = 0.033* p  = 0.957* Cardiac troponin-I (ng/ml) \\u2003Group A 0.02 (0.01–0.022) 0.22 (0.07–0.85) 0.13 (0.03–0.75) <0.001 † \\u2003Group B 0.01 (0.01–0.016) 0.66 (0.10–1.28) 0.19 (0.03–0.80) <0.001 † p  = 0.520* p  = 0.018* p  = 0.097* Data presented as the median (range). t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  † Intraindividual differences (Friedman test), *between-group differences (Kruskal–Wallis test).   Figure 1Procalcitonin plasma levels before operation and 24 hours after cardiopulmonary bypass. Procalcitonin (PCT) plasma levels in the treated and control groups, before operation (t1) and 24 hours after cardiopulmonary bypass (t5). Significant elevation was found in both groups (*Friedman tests). After the operation, procalcitonin was lower in group A. The between-group difference was significant (+ Kruskal–Wallis test).  Figure 2IL-8 plasma levels before operation and after cardiopulmonary bypass. IL-8 plasma levels in the treated and control groups, before operation (t1) and 10 minutes (t2) and 2 hours (t3) after cardiopulmonary bypass. Significant elevation was found in both groups (*Friedman tests). At t2 and t3 the IL-8 plasma levels were lower in group A. The between-group differences were significant (+Kruskal–Wallis test).  Figure 3Soluble intercellular adhesion molecule 1 plasma levels before operation and after cardiopulmonary bypass. Soluble intercellular adhesion molecule 1 (ICAM-1) plasma levels in the treated and control groups, before operation (t1) and 24 hours (t5) and 44 hours (t6) after cardiopulmonary bypass. No elevation was found in group A, but the elevation was significant in group B (*Friedman tests). The between-group differences were significant after cardiac surgery on cardiopulmonary bypass (+Kruskal–Wallis test).  No difference was found between CABG and AVR patients in the inflammatory markers or cTr-I, except for ICAM-1 in group B, which was higher among AVR patients before operation (p = 0.047) and at the 24-hour timepoint (p = 0.023).  Patients with postoperative atrial fibrillation or pacemaker rhythm in the VVI mode (group A, five patients; group B, four patients) were excluded from the analysis of haemodynamic data. The cardiac index and stroke volume index were higher while the SVRI figures were lower in group A, with an observed statistical power of 83%. The intrathoracic blood volume index, stroke volume variation, heart rate, arterial blood pressure (systolic) (p = 0.787), arterial blood pressure (diastolic) (p = 0.771) and extravascular lung water index (p = 0.326) did not differ between the two groups (Table 3).  Table 3 Results of the haemodynamic data t1 t2 t3 t4 t5 t6 p  value a Heart rate (l/min) 0.925 \\u2003Group A 60 ± 12 76 ± 14 78 ± 13 84 ± 18 84 ± 7 92 ± 10 \\u2003Group B 59 ± 8 72 ± 9 78 ± 12 81 ± 12 87 ± 12 97 ± 12 Stroke volume index (ml/m 2 ) 0.026 \\u2003Group A 38.5 ± 6.5 33.5 ± 9.1 31.9 ± 8.2 32.8 ± 9.0 36.9 ± 13.8 36.1 ± 7.4 \\u2003Group B 36.4 ± 5.7 30.2 ± 5.8 27.6 ± 8.0 27.6 ± 7.5 31.3 ± 10.0 30.1 ± 5.0 Cardiac index (l/min/m 2 ) 0.010 \\u2003Group A 2.3 ± 0.45 2.4 ± 0.39 2.4 ± 0.63 2.7 ± 0.63 3.0 ± 0.98 3.4 ± 0.94 \\u2003Group B 2.2 ± 0.36 2.2 ± 0.31 2.0 ± 0.41 2.2 ± 0.44 2.6 ± 0.38 2.9 ± 0.49 Stroke volume variation (%) 0.873 \\u2003Group A 1.5 ± 0.8 2.3 ± 3.3 3.4 ± 5.3 2.2 ± 1.8 4.5 ± 11.5 2.0 ± 0.7 \\u2003Group B 2.6 ± 3.9 3.1 ± 2.9 4.9 ± 8.5 2.8 ± 3.1 2.5 ± 1.5 2.5 ± 1.0 Intrathoracic blood volume index (ml/m 2 ) 0.387 \\u2003Group A 861 ± 132 829 ± 129 875 ± 120 882 ± 122 923 ± 137 975 ± 136 \\u2003Group B 845 ± 153 811 ± 151 831 ± 192 831 ± 169 871 ± 128 919 ± 214 Systemic vascular resistance index (dyn s/cm 5  m 2 ) 0.005 \\u2003Group A 2,663 ± 414 2,031 ± 492 2,701 ± 604 † 2,418 ± 534 2,076 ± 514 2,052 ± 430 \\u2003Group B 2,732 ± 424 2,279 ± 428 3,499 ± 964 2,902 ± 659 2,470 ± 505 2,227 ± 507 Data presented as the mean ± standard deviation. t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  a Between-group differences, general linear model repeated measurement analysis (analysis of variance).  † p  < 0.05 (with Bonferroni adjustment for multiple comparison).BODY.DISCUSSION:For the first time according to the literature, we have shown in the present investigation that dextran-70 reduces the inflammatory cytokine response, reduces the peak levels of serum procalcitonin and reduces the peak levels of the markers of endothelial activation or damage during the inflammatory activation following CPB. Earlier investigation had indicated that dextran-70 reduces complement-3 activation product levels during cardiopulmonary bypass [28], but subsequently it was revealed that fresh frozen plasma, which was applied in the control group in large volume, contains a high level of complement-3 [29].  The exact mechanism of the anti-inflammatory effect of dextran is still unclear. Intravital studies on haemodilution in controlled ischaemia have shown that dextran reduces leukocyte adhesion onto the endothelium. The inhibition of leukocyte–endothelium interaction already occurs in the pharmacological microdose of dextran, independently of the haemodilution effect [8]. On the basis of recently published experimental data, dextran inhibits neutrophil adhesion by a neutrophil-dependent mechanism, regulating integrin function rather than interfering with endothelial cell activation [23]. In the same experimental setting, gelatin represented a similar effect on neutrophil adhesion to that of dextran; therefore, it can be supposed that other mechanisms should also be of importance. The termination of a neutrophil-mediated inflammatory response is effected through apoptosis of the neutrophils. When PMNs were exposed to dextran in whole blood samples, significant apoptosis was demonstrated. By these effects, human PMN survival was found to decrease [30]. Inflammatory mediators also modulate PMN survival. IL-8 plays a major role in the markedly reduced rate of programmed cell death of neutrophils after CPB [31]. In the present investigation we have demonstrated the attenuation of IL-8 release by dextran-70. The free radical scavenger effect of dextran is also well known [8]. This action may contribute to the reduction of endothelial activation and injury after CPB, as clearly demonstrated in our investigation.  From the good predictive value of procalcitonin [6] and its blunted kinetics in the dextran-treated group in our study, one can suppose that dextran-70 may influence the patients' outcome after CPB. Further large-scale studies are required to confirm this assumption.  In our investigation a similarly blunted peak level of IL-8 was found after dextran-70 administration as that reported earlier by Wan and colleagues on coronary patients operated on without CPB [32]. IL-8 plays an important role in the formation of the myocardial and pulmonary ischaemia-reperfusion injury developing after the use of CPB [3,7,33]. Its serum concentration correlates with postoperative cTr-I values [33]. The peak plasma IL-8 level also correlates with the magnitude of the proximal tubular injury following CABG surgery [34]. On the basis of our results, a lower IL-10 peak concentration occurred proportionally with the IL-8 peak level when dextran infusion was used, which indicates that no imbalance developed between proinflammatory and anti-inflammatory responses. High doses of aprotinin or a heparin-coated CPB tubing set also reduce IL-10 production following CPB [33,35]. Steroids increase the concentration of IL-10 with the consequences of immune suppression [35,36].  We found no significant action of dextran-70 on the levels of C-reactive protein, IL-6 and IL-6r, but the peak concentration of IL-6 and C-reactive protein was lower and that of IL-6r was higher in the group administered dextran. Previous investigations proved that IL-6 [33,37] and C-reactive protein [2] levels did not differ in CABG and off-pump coronary artery bypass surgery, but reduced IL-6 levels occurred after minimally invasive direct coronary artery bypass surgery, which suggests that operative trauma itself rather than CPB or ischaemia-reperfusion injury initiates the release of these factors [2]. These results suggest that dextran can reduce the inflammation resulted from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma.  There is an increasing body of evidence that the damaging effect of ischaemia-reperfusion in the heart is related to inflammatory processes [3] and that attenuation of the inflammatory response improves myocardial outcome following cardiac surgery [36]. The pattern of cardiac cTr-I release is similar after CABG and after valve surgery, but off-pump coronary artery bypass surgery results in less elevation than CABG using CPB [38]. Troponin-I release was reduced in the patient group where dextran-70 was applied, which may indicate that dextran-70 decreases the ischaemia-reperfusion injury after cardiac operation. The difference in cTr-I was rather small between the two groups, and therefore its clinical relevance must be confirmed in a large-scale study.  In our investigation dextran infusion has increased the stroke volume index independently of the preload by the reduction of the systemic vascular resistance index. Although the intrathoracic blood volume index and stroke volume variation did not differ between the groups it cannot be excluded that the observed differences in haemodynamics are partly due to the different volume effects of dextran and gelatin – whereas on the basis of our sELAM-1 and soluble ICAM-1 results, dextran infusion reduces the degree of the endothelial damage and activation. Particularly high preoperative sELAM-1 plasma concentration figures were found in the dextran group in contrast to the control group, indicating higher preoperative endothelial dysfunction among these patients. The levels of sELAM-1 and ICAM-1 significantly increased in the control group, but did not change in those patients who received dextran. This effect on the activation and damage of the endothelium may explain dextran's favourable influence on the vasomotor regulatory disturbance. Cardiopulmonary bypass alters vasomotor regulation, reducing the endothelium-dependent relaxation [39]. The nitric oxide production is significantly reduced up to 6 hours after CPB [40], which coincides with the time interval where the main difference in the SVRI was found in our study.  For the statistical analysis, six series of observations were represented over time to show the haemodynamic status at every examined timepoint of the inflammatory mediators. Using Bonferroni correction for multiple comparison, these many timepoints have resulted in a very high correction factor, increasing the possible statistical error, which may mask real differences. Although the observed statistical power was high, particularly in case of the SVRI, the clinical relevance of these finding must be justified in a study investigating a larger population.  The administration of HES 130/0.4 has also been investigated on the inflammatory response in other patient populations (for example, in patients undergoing major abdominal surgery). The IL-6, IL-8 and soluble ICAM-1 release was found to be lower in the HES-treated group, but the concentration of sELAM-1 was similar in the HES-treated and in the lactated Ringer's solution-treated groups [20]. Although HES does possesses anti-inflammatory properties [17,18], as the authors concluded these results were probably due to differences in microcirculation, because crystalloid-based volume therapy may worsen the microcirculatory blood flow and tissue oxygenation despite sufficient haemodynamic conditions [41]. The microhaemodynamic status was not measured in our investigation, but previously gelatin had been shown to increase cerebral blood flow velocity and to improve cutaneous microcirculation, more expressively than HES, during haemodilution (to a haematocrit level of 30.0%). That effect on microcirculation was related inversely to haematocrit, which means that after autologue blood retransfusion the parameters of cutaneous microcirculation have worsened [42]. Similarly to dextran, in our investigation HES was shown to diminish the endothelial activation or damage in critically ill patients. The soluble ICAM-1 and sELAM-1 levels did not increase following HES administration compared with the increase of these molecular levels in the control group treated with human albumin (20%).  On the basis of comparative animal experiments investigating the effects of colloids on leukocyte-endothelial interaction we have investigated the presumably most effective colloid, dextran-70, during CPB and we have proved its anti-inflammatory effect. Having said that, questions still remain of whether dextran has any advantage over other colloids in the anti-inflammatory properties in clinical situations, and whether it results in real clinical benefit on patient outcome. Further clinical studies are required to compare the anti-inflammatory effect of dextran with that of HES, and large-scale clinical studies must justify that the reduction of inflammation by dextran can be translated into clinical benefit. Another question to be raised is whether dextran administrated in a microdose is, or is not, able to reduce the inflammation in clinical situations of systemic inflammatory response syndrome, as in experimental studies [8], because microdose administration eliminates the antihaemostatic effects.  Blood loss was higher in the dextran group than the control group, which can be explained by the higher antihaemostatic potential. This difference, however, is surprisingly not clinically significant, since the number of red blood cell transfusions and haematocrit levels did not differ.  The limitation of this study is that gelatin, or any other colloid, administrated in the control group cannot be considered neutral concerning the inflammatory response. An infusion possessing anti-inflammatory effects is more acceptable for the control group than an infusion with proinflammatory features. Although gelatin administration did not influence neutrophil infiltration, NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity in a septic model [17], a moderate favourable effect on inflammation was indicated, reducing the Ba fragment of the complement cascade [24] and impairing the firm leukocyte adhesion in an in vitro model [23]. Certain albumin batches possess well-documented proinflammatory actions (for example, activating E-selectin, ICAM-1, vascular cell adhesion molecule 1), which seriously question the relevance of human albumin as a valid control for studies concerning inflammation [43]. Also, the use of lactated Ringer infusion is associated with significant neutrophil activation [44] and early expression of endothelial E-selectin and P-selectin [45]. Another limitation of this study is the single institutional setting. There were no differences in morbidity, mortality or length of intensive care unit stay between the groups but the low number of patients in our study does not allow one to conclude on the clinical outcome parameters.BODY.CONCLUSION:To the best of our knowledge our investigation is the first to show that dextran-70 reduces the inflammatory cytokine response, the liberation of some soluble adhesion molecules and the peak level of procalcitonin following cardiac operations. These results suggest that dextran can reduce the inflammation resulting from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma. Further large-scale clinical studies are required to demonstrate this effect on patient outcome after cardiac surgery.BODY.KEY MESSAGES:• Dextran-70 reduces the inflammatory activation after CPB.BODY.ABBREVIATIONS:AVR = aortic valve replacement; CABG = coronary artery bypass grafting; CPB = cardiac surgery on cardiopulmonary bypass; cTr-I = cardiac troponin I; ELISA = enzyme-linked immunosorbent assay; HES = hydroxyethyl starches; ICAM-1 = intercellular adhesion molecule-1; IL = interleukin; NF = nuclear factor; PMN = polymorphonuclear leukocyte; sELAM-1 = soluble endothelial leukocyte adhesion molecule-1; SVRI = systemic vascular resistance index; TNF = tumour necrosis factor.BODY.COMPETING INTERESTS:The authors declare that they have no competing interests.BODY.AUTHORS' CONTRIBUTIONS:KG conceived the study, participated in the design, coordination, measurements and acquisition of data, performed the statistical analysis, drafted the manuscript and obtained sponsorship. AB made a substantial contribution to the execution of the study and acquisition of data. NA and LB made a substantial contribution to the design of the study, interpretation of the data and provided critical review of the manuscript. NA participated in the coordination of the study. GK participated in the study design and helped to write the manuscript. VG and JG carried out the immunoassays, discussed the results and provided a critical review of the manuscript. TK carried out laboratory measurements, discussed the results and provided a critical review of the manuscript. All authors read and approved the final manuscript.\", \"TITLE: Influence of dextran-70 on systemic inflammatory response and myocardial ischaemia-reperfusion following cardiac operationsABSTRACT.INTRODUCTION:Experimental studies have demonstrated that dextran-70 reduces the leukocyte–endothelium interaction, but clinical evidence is still lacking. Our objective was to justify the anti-inflammatory effect of dextran-70 following cardiac operations.ABSTRACT.METHODS:Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20). The plasma concentration of procalcitonin, C-reactive protein, IL 6, IL 6r, IL 8, IL 10, soluble endothelial leukocyte adhesion molecule-1, soluble intercellular adhesion molecule-1, cardiac troponin-I and various haemodynamic parameters were measured in the perioperative period. Multivariate methods were used for statistical analysis.ABSTRACT.RESULTS:In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found. There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups. Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.ABSTRACT.CONCLUSION:Our investigation demonstrated that the use of dextran-70 reduces the systemic inflammatory response and cardiac troponin-I release following cardiac operation.ABSTRACT.TRIAL REGISTRATION NUMBER:ISRCTN38289094.BODY.INTRODUCTION:Cardiac surgery on cardiopulmonary bypass (CPB) results in a complex immune response characterized by the activation of all inflammatory pathways and strongly related to increased postoperative morbidity and mortality. The immune activation due to systemic inflammatory response syndrome exposes the patient to postoperative wound healing complications and to the development of infections [1,2].  Increased levels of the proinflammatory cytokines IL-6 and IL-8 play a major role in the pathogenesis of ischaemia-reperfusion injury [3] and multiple organ dysfunction syndrome [4]. IL-8 is a crucial chemokine, which attracts and activates polymorphonuclear leukocytes (PMNs) as well as T lymphocytes, and controls their migration. Tissue penetration, free radical production, and granulocyte elastase synthesis and release are also increased in PMNs [4]. Serum procalcitonin is a sensitive marker for the early detection of systemic inflammatory response syndrome [5]. Procalcitonin levels above 2 ng/ml are predictive for postoperative complications after cardiac operations [6]. Owing to inflammation, soluble adhesion molecules are shed into the circulation and their concentration correlates with the magnitude of endothelial activation and injury [1,7].  Several investigations have demonstrated that artificial colloids modulate the inflammatory response. Animal experiments have confirmed that dextran decreases the endothelial adhesion of PMNs in the postischaemic phase independently of the haemodilution [8]. Among trauma patients, dextran administration counteracts monocyte dysfunction and the related imbalance between coagulation and fibrinolysis [9]. Hypertonic saline dextran suppressed myocardial TNF-α, IL-1β and IL-6 secretion after an initial burn injury in an animal study, improving ventricular performance after subsequent septic challenge [10]. Experimental and clinical studies have justified the beneficial effects of dextran in the prevention of acute respiratory distress syndrome following trauma and sepsis [11], radiation injury [12], pancreatitis [13] and lower limb reperfusion injury [14].  It has been reported that hydroxyethyl starches (HES) reduce capillary leakage [15], leading to the concept of 'plugging the leaks' in various diseases, including sepsis and burns [16]. In a polymicrobial sepsis model, HES inhibited the inflammatory cytokine response, neutrophil infiltration and expression of intercellular adhesion molecule-1 (ICAM-1) mRNA [17]. Other anti-inflammatory manifestations of low-molecular-weight HES include impaired neutrophil respiratory burst and reduced neutrophil chemotaxis [18]. Administration of HES was associated with reduced markers of inflammation and endothelial activation in sepsis [19] and in patients undergoing major abdominal surgery [20].  Without any evidence of modulating the inflammatory response, gelatin infusion has been considered pharmacologically inert [21]. This assumption was confirmed in an experimentally induced acute lung injury model, where the inflammatory response (TNF-α) and oxidative stress were not affected by gelatin [22]. A recently published investigation has also indicated that NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity were not affected by modified fluid gelatin in a polymicrobial sepsis model [17] – whereas, like other artificial colloids, gelatin impairs firm leukocyte adhesion to the endothelium in vitro [23], and applied in the priming fluid gelatin reduces the contact activation of complement cascades by binding to fragment Ba [24]. Nevertheless an increased TNF-α release was demonstrated after the incubation of blood with gelatin in vitro [25], but in vivo investigation has revealed that gelatin does not alter PMN function [26].  Despite numerous studies having been published concerning the influence of colloids on inflammation, only few comparative studies exist. Reducing the endothelial adhesion of PMNs, dextran was reported to be more potent than HES in leukocyte-related reperfusion injury, and in contrast to HES the anti-inflammatory effect of dextran developed even in nondilutional microdose administration [8].  On the basis of experimental data it may be hypothesized that dextran attenuates the inflammatory response following cardiac surgery. There are, however, no exact clinical data in the literature that would support the anti-inflammatory effect of dextran following cardiac surgery. Our objective was the investigation of the effects of dextran-70 compared with gelatin as a control, on the levels of serum procalcitonin, on the inflammatory cytokine response, the markers of endothelial damage, myocardial ischaemia-reperfusion injury and haemodynamics after CPB. Our hypothesis was that administration of dextran reduces the level of inflammatory mediators and cardiac troponin-I (cTr-I) at the most important timepoints.BODY.MATERIALS AND METHODS:With permission from the ethical committee of the hospital, 40 patients undergoing elective first-time CPB – 32 patients undergoing coronary artery revascularization (coronary artery bypass grafting (CABG)), eight patients undergoing aortic valve replacement (AVR) – were involved in this prospective, randomized, double-blind study after individual consent was obtained. The setting of the study was single institutional. Two experienced anaesthesiologists and two experienced surgeons were involved in the study. Exclusion criteria were as follows: 'redo' operation, hepatic disease, renal dysfunction, immunologic disease, steroid treatment, intake of aspirin or other cyclooxygenase inhibitor within 7 days prior to surgery, or known allergy to volume expanders used in the study. None of the patients received volatile anaesthetics, steroids or aprotinin and haemofiltration was not used either. No shed mediastinal blood was retransfused during the postoperative period.  Two groups were formed following computerized randomization. Twenty patients (CABG, 17 patients; AVR, three patients) were given dextran-70 (6%; average molecular weight 70,000 Da) infusion (Macrodex; Pharmalink, Inc., Upplands Väsby, Sweden) (group A), while in the control group 20 patients (CABG, 15 patients; AVR, five patients) were given oxypolygelatin (5.5%; average molecular weight 30,000 Da) infusion (Gelifundol; Biotest Pharma, Inc., Dreieich, Germany) (group B). Following the induction of anaesthesia, artificial colloid was administered using infusion pumps (Model 591; IVAC, Inc., San Diego, CA, USA). After the application of hapten inhibition by 20 ml dextran-1 (Promit; Fresenius Kabi, Inc., Norge AS, Norway), dextran-70 infusion was used at the dose of 7.5 ml/kg for 30 minutes before CPB, and at a dose of 12.5 ml/kg for 14 hours following the cessation of CPB. Gelatin was infused by the same body-weight-based volume as dextran. The indication of the colloid administration was volume substitution. Depending on the actual haemodynamic and volume status, crystalloid infusion was administered together with a fixed dose of colloid.  Anaesthesia was carried out by a standardized total intravenous method. Premedication was achieved with midazolam. For the induction of anaesthesia, midazolam, propofol in a target controlled infusion perfusion device using DiprifusorTM (Alaris Medical Systems, Hampshire, UK), alfentanil and pipecuronium were used, while propofol (target controlled infusion) and alfentanil were given to maintain anaesthesia. Anticoagulation was maintained with heparin (initial value 300 IU/kg) to keep the activated clotting time longer than 400 seconds. Protamine was administered in a 1:1 ratio based on the initial heparin bolus (necessary to achieve the target activated clotting time). Cardiopulmonary bypass was carried out in normothermia, with the use of a roller pump (Cobe Cardiovascular, Inc., Arvada, Colorado USA), with pulsatile flow rate of 2.4 l/min/m2 and a membrane oxygenator (AffinityTM NT 541; Medtronic, Inc., Minneapolis, MN, USA). Antegrade, cold, crystalloid cardioplegia (modified Bretschneider solution) injected into the aortic root was used for myocardial protection. The Pulsion PiCCOTM (Pulsion Medical Systems, Inc., München, Germany) device was used for haemodynamic monitoring.  Packed red blood cell administration was applied when the haemoglobin level was less then 90 g/l, or during CPB when haemoglobin was below 70 g/l. Postoperative complications were defined as follows: cardiovascular complication (low cardiac output with cardiac index <2.2 l/min/m2 after volume infusion, requiring the use of positive inotrop agents and/or intraaortic balloon pump); perioperative myocardial infarction with typical electrocardiogram changes and creatine kinase MB >75 U/ml (three times the upper limit of the reference range); acute lung injury (prolonged ventilation, PaO2/FiO2 ratio <200); acute renal failure (serum creatinine >230 μmol/l); neurologic complications (stroke, ischaemic insults); gastrointestinal complications (ischaemia, bleeding); and infections.  Arterial blood samples were taken from the indwelling femoral artery cannula at the following time intervals: t1, before anaesthesia; t2, 10 minutes after CPB; t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; and t6, 44 hours after CPB. At the same timepoints, the following haemodynamic parameters were registered: heart rate, arterial blood pressure, cardiac index, stroke volume index, stroke volume variation, systemic vascular resistance index (SVRI), intrathoracic blood volume index, and extravascular lung water index. The haematocrit (packed cell volume), haemoglobin and blood cell count were measured at all time intervals. Determination of the plasma concentration of inflammatory mediators – interleukins (IL-6, IL-6r, IL-8, IL-10) and soluble adhesion molecules (soluble endothelial leukocyte adhesion molecule-1 (sELAM-1), soluble ICAM-1) – was carried out by ELISA (DIACLONE ResearchTM, Besançon, France) complying with the technologic regulations of the manufacturer. Blood samples were centrifuged with a cooled centrifuge at 1,000 × g for 15 minutes. Centrifuged plasma was stored at -86°C.  Three plasma samples were analysed for cytokine and soluble adhesion molecule levels with the sampling timepoints based on the kinetics of the single mediators according to the data in the literature. In each case the first measurement point was the preoperative control value, the second was the expected maximal value of the given mediator after cardiac surgery, while the third measurement point was the value corresponding to the dropoff phase [1,7]. The t1, t3 and t4 samples were analysed for IL-6 and IL-6r, while for IL-8 and IL-10 determinations the t1, t2, and t3 samples were used. Monitoring of the adhesion molecules was done as follows: sELAM-1 at the t1, t4 and t5 timepoints, and soluble ICAM-1 as the t1, t5 and t6 samples. The average of the duplicated ELISA test results was corrected using the following equation: corrected concentration = noncorrected concentration × actual plasma fraction/plasma fraction of the t1 sample. Procalcitonin was measured using an immunoluminometric assay (reference range 0–0.5 ng/ml; LUMItestTM; BRAHMS GmbH, Berlin, Germany). For the measurement of serum C-reactive protein the immune turbidimetric method was used (reference range 0–10 mg/l; DIALABTM, Vienna, Austria). cTr-I was measured by a two-site immunoluminometric assay (reference range 0–0.03 ng/ml; LIAISONTM Troponin I; DiaSorin S.p.A, Saluggia, Italy). For procalcitonin measurements we used the t1 and t5 blood samples, while for C-reactive protein the t1, t5 and t6 samples were used, and for cTr-I the t1, t4, t5 and t6 samplings were used.BODY.MATERIALS AND METHODS.STATISTICAL ANALYSIS:Statistical analysis was performed by SPSS for Windows 9.0 software (SPSS Inc., Chicago, Illinois, USA). After obtaining the results for 22 patients a midterm analysis was performed to calculate the necessary total sample size – Altman's nomogram [27] was used after calculating the standardized difference of the inflammatory mediators, setting the statistical power at 80% and choosing a 5% significance level. In the case of IL-8, IL-10, ICAM-1 and procalcitonin, the standardized difference and the necessary sample size were (0.924) 36, (0.886) 39, (1.326) 19 and (1.041) 29, respectively. According to the midterm analysis the sample size was determined to be 40 patients.  For the comparison of the basic data, the chi-squared test and Student's t test were used. We checked the parameters for normal distribution by the Kolmogorov–Smirnov test. If the result proved significant, the nonparametric test was used consecutively. Among inflammatory markers and cTr-I, nonparametric methods were used (Kruskal–Wallis test, Friedman test); and for haemodynamic parameters the general linear model repeated-measurement analysis (analysis of variance) with Bonferroni adjustment for multiple comparison was used for the analysis of the intraindividual and interindividual differences. Any difference was regarded statistically significant if p < 0.05. The results are displayed in the form of the mean ± standard deviation, as the median (range), or as a box-plot where the median, 25–75% and 2.5–97.5% percentile ranges are depicted.BODY.RESULTS:Past medical and perioperative data of the two groups are presented in Table 1. No operative mortality, low cardiac output, lung injury, renal failure, neurological complications, gastrointestinal complications, surgical intraoperative problems or wound healing problems occurred among the patients involved in the study. Myocardial infarction had developed in three cases, one case in group A and two cases in group B. Positive inotrope drug was not applied after the operation, and no differences were found in the frequency of vasodilator therapy (p = 0.584) or β-blocker therapy (p = 0.333) between the groups. The total postoperative mediastinal and pleural drainage proved to be higher in group A. Nevertheless, the amount of the transfused red blood cell units did not differ between the two groups. There was also no significant difference between the preoperative and the 44-hour postoperative haematocrit values, which indicates that the red blood cell loss was approximately the same in both groups.   Table 1 Anamnestic and perioperative data Group A Group B p  value a Age (years) 61.1 ± 6.5 62.5 ± 7.6 0.535 Gender (male/female) 13/7 14/6 0.736 Body mass index (kg/m 2 ) 28.7 ± 3.9 28.9 ± 3.8 0.821 Hypertension (%) 47.2 52.8 0.292 Diabetes mellitus (type I/type II/impaired glucose tolerance) (%) 2/4/1 2/3/1 0.733 Preoperative ejection fraction (%) 55.6 ± 12.6 56.1 ± 9.7 0.906 EuroScore (log) (%) 2.5 ± 1.2 2.9 ± 1.4 0.405 Amount of plasma substitute (ml) 1626 ± 212 1606 ± 205 0.725 Amount of crystalloids (ml) 4172 ± 660 4107 ± 665 0.765 Number of anastomoses (coronary artery bypass graft) 3.5 ± 1.0 3.5 ± 0.9 0.991 Aortic Xclamp (min) 53 ± 13.8 59 ± 18.1 0.403 Cardiac surgery on cardiopulmonary bypass duration (min) 83 ± 23.7 90 ± 29.3 0.401 Operation time (min) 249 ± 64.5 258 ± 61.7 0.634 Minimum rectal temperature (°C) 34.8 ± 0.6 35.0 ± 0.5 0.274 Preoperative packed cell volume 0.40 ± 0.034 0.39 ± 0.040 0.723 Postoperative 44 hours packed cell volume 0.30 ± 0.035 0.30 ± 0.035 0.623 Postoperative drainage (44 hours, ml) 818 ± 286 588 ± 179 0.005 Red blood cell transfusion (U) 1.8 ± 1.3 1.6 ± 1.2 0.548 Extubation time (hours) 9.2 ± 4.1 9.3 ± 4.6 0.894 Intensive care unit stay (hours) 54 ± 23 47 ± 6 0.209 Hospital stay (days) 9.9 ± 2.4 8.9 ± 1.3 0.114 Data presented as the mean ± standard deviation.  a Chi-squared test or Student's  t  test.   The peak level of procalcitonin was lower in group A (Figure 1.). The procalcitonin level was below 2 ng/ml for all of the patients in group A, but it increased in 40% of the patients in group B with a peak level higher than 2 ng/ml (P = 0.001). IL-8 level elevation was moderate in group A in contrast to the increase experienced in the control group, which is a well-known characteristic of CPB. The between-group difference in IL-8 was significant after CPB (Figure 2). The same kinetics were found for IL-10 (Table 2). The preoperative concentration of sELAM-1 was higher in group A, and did not increase any further, in contrast to the control group that started at a low preoperative value and subsequently rose significantly (Table 2). The level of soluble ICAM-1 did not show any increase in group A. On the contrary, there was a significant and characteristic increase in the control group. The between-group differences for soluble ICAM-1 were significant after CPB (Figure 3). No significant difference was found in C-reactive protein, IL-6 or IL6r between the groups. The cTr-I levels were lower in group A, especially at the t5 timepoint (Table 2).  Table 2 Results of the inflammatory mediators and cardiac troponin I t1 t2 t3 t4 t5 t6 p C-reactive protein (mg/l) \\u2003Group A 3.7 (1.0–22.6) 79.9 (50.0–131.7) 112.0 (61.1–177.6) <0.001 † \\u2003Group B 2.6 (0.6–10.5) 87.6 (52.4–143.0) 131.0 (71.0–228.0) <0.001 † p  = 0.068* p  = 0.092* p  = 0.168* IL-6 (pg/ml) \\u2003Group A 1.6 (0.4–21.8) 95.0 (13.6–405.1) 46.3 (16.1–149.5) <0.001 † \\u2003Group B 2.0 (0.4–60.6) 130.5 (21.7–353.8) 49.2 (14.8–214.5) <0.001 † p  = 0.107* p  = 0.829* p  = 0.482* IL-6r (ng/ml) \\u2003Group A 43.6 (1.7–125.0) 47.4 (0.7–109.5) 56.2 (25.2–226.3) 0.949 † \\u2003Group B 40.7 (15.6–94.6) 42.4 (22.2–100.5) 50.2 (13.2–104.9) 0.861 † p  = 0.607* p  = 0.914* p  = 0.304* IL-10 (pg/ml) \\u2003Group A 1.9 (0.2–24.0) 47.2 (2.3–476.6) 7.2 (1.3–90.9) <0.001 † \\u2003Group B 2.6 (0.8–9.7) 209.7 (16.3–814.3) 56.1 (3.6–225.1) <0.001 † p  = 0.136* p  = 0.001* p  = 0.001* Soluble endothelial leukocyte adhesion molecule-1 (ng/ml) \\u2003Group A 88.6 (49.8–194.5) 88.5 (14.4–189.6) 72.7 (8.9–163.1) 0.058 † \\u2003Group B 49.0 (18.3–144.1) 130.7 (33.0–360.7) 72.6 (16.7–224.7) <0.001 † p  < 0.001* p  = 0.033* p  = 0.957* Cardiac troponin-I (ng/ml) \\u2003Group A 0.02 (0.01–0.022) 0.22 (0.07–0.85) 0.13 (0.03–0.75) <0.001 † \\u2003Group B 0.01 (0.01–0.016) 0.66 (0.10–1.28) 0.19 (0.03–0.80) <0.001 † p  = 0.520* p  = 0.018* p  = 0.097* Data presented as the median (range). t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  † Intraindividual differences (Friedman test), *between-group differences (Kruskal–Wallis test).   Figure 1Procalcitonin plasma levels before operation and 24 hours after cardiopulmonary bypass. Procalcitonin (PCT) plasma levels in the treated and control groups, before operation (t1) and 24 hours after cardiopulmonary bypass (t5). Significant elevation was found in both groups (*Friedman tests). After the operation, procalcitonin was lower in group A. The between-group difference was significant (+ Kruskal–Wallis test).  Figure 2IL-8 plasma levels before operation and after cardiopulmonary bypass. IL-8 plasma levels in the treated and control groups, before operation (t1) and 10 minutes (t2) and 2 hours (t3) after cardiopulmonary bypass. Significant elevation was found in both groups (*Friedman tests). At t2 and t3 the IL-8 plasma levels were lower in group A. The between-group differences were significant (+Kruskal–Wallis test).  Figure 3Soluble intercellular adhesion molecule 1 plasma levels before operation and after cardiopulmonary bypass. Soluble intercellular adhesion molecule 1 (ICAM-1) plasma levels in the treated and control groups, before operation (t1) and 24 hours (t5) and 44 hours (t6) after cardiopulmonary bypass. No elevation was found in group A, but the elevation was significant in group B (*Friedman tests). The between-group differences were significant after cardiac surgery on cardiopulmonary bypass (+Kruskal–Wallis test).  No difference was found between CABG and AVR patients in the inflammatory markers or cTr-I, except for ICAM-1 in group B, which was higher among AVR patients before operation (p = 0.047) and at the 24-hour timepoint (p = 0.023).  Patients with postoperative atrial fibrillation or pacemaker rhythm in the VVI mode (group A, five patients; group B, four patients) were excluded from the analysis of haemodynamic data. The cardiac index and stroke volume index were higher while the SVRI figures were lower in group A, with an observed statistical power of 83%. The intrathoracic blood volume index, stroke volume variation, heart rate, arterial blood pressure (systolic) (p = 0.787), arterial blood pressure (diastolic) (p = 0.771) and extravascular lung water index (p = 0.326) did not differ between the two groups (Table 3).  Table 3 Results of the haemodynamic data t1 t2 t3 t4 t5 t6 p  value a Heart rate (l/min) 0.925 \\u2003Group A 60 ± 12 76 ± 14 78 ± 13 84 ± 18 84 ± 7 92 ± 10 \\u2003Group B 59 ± 8 72 ± 9 78 ± 12 81 ± 12 87 ± 12 97 ± 12 Stroke volume index (ml/m 2 ) 0.026 \\u2003Group A 38.5 ± 6.5 33.5 ± 9.1 31.9 ± 8.2 32.8 ± 9.0 36.9 ± 13.8 36.1 ± 7.4 \\u2003Group B 36.4 ± 5.7 30.2 ± 5.8 27.6 ± 8.0 27.6 ± 7.5 31.3 ± 10.0 30.1 ± 5.0 Cardiac index (l/min/m 2 ) 0.010 \\u2003Group A 2.3 ± 0.45 2.4 ± 0.39 2.4 ± 0.63 2.7 ± 0.63 3.0 ± 0.98 3.4 ± 0.94 \\u2003Group B 2.2 ± 0.36 2.2 ± 0.31 2.0 ± 0.41 2.2 ± 0.44 2.6 ± 0.38 2.9 ± 0.49 Stroke volume variation (%) 0.873 \\u2003Group A 1.5 ± 0.8 2.3 ± 3.3 3.4 ± 5.3 2.2 ± 1.8 4.5 ± 11.5 2.0 ± 0.7 \\u2003Group B 2.6 ± 3.9 3.1 ± 2.9 4.9 ± 8.5 2.8 ± 3.1 2.5 ± 1.5 2.5 ± 1.0 Intrathoracic blood volume index (ml/m 2 ) 0.387 \\u2003Group A 861 ± 132 829 ± 129 875 ± 120 882 ± 122 923 ± 137 975 ± 136 \\u2003Group B 845 ± 153 811 ± 151 831 ± 192 831 ± 169 871 ± 128 919 ± 214 Systemic vascular resistance index (dyn s/cm 5  m 2 ) 0.005 \\u2003Group A 2,663 ± 414 2,031 ± 492 2,701 ± 604 † 2,418 ± 534 2,076 ± 514 2,052 ± 430 \\u2003Group B 2,732 ± 424 2,279 ± 428 3,499 ± 964 2,902 ± 659 2,470 ± 505 2,227 ± 507 Data presented as the mean ± standard deviation. t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  a Between-group differences, general linear model repeated measurement analysis (analysis of variance).  † p  < 0.05 (with Bonferroni adjustment for multiple comparison).BODY.DISCUSSION:For the first time according to the literature, we have shown in the present investigation that dextran-70 reduces the inflammatory cytokine response, reduces the peak levels of serum procalcitonin and reduces the peak levels of the markers of endothelial activation or damage during the inflammatory activation following CPB. Earlier investigation had indicated that dextran-70 reduces complement-3 activation product levels during cardiopulmonary bypass [28], but subsequently it was revealed that fresh frozen plasma, which was applied in the control group in large volume, contains a high level of complement-3 [29].  The exact mechanism of the anti-inflammatory effect of dextran is still unclear. Intravital studies on haemodilution in controlled ischaemia have shown that dextran reduces leukocyte adhesion onto the endothelium. The inhibition of leukocyte–endothelium interaction already occurs in the pharmacological microdose of dextran, independently of the haemodilution effect [8]. On the basis of recently published experimental data, dextran inhibits neutrophil adhesion by a neutrophil-dependent mechanism, regulating integrin function rather than interfering with endothelial cell activation [23]. In the same experimental setting, gelatin represented a similar effect on neutrophil adhesion to that of dextran; therefore, it can be supposed that other mechanisms should also be of importance. The termination of a neutrophil-mediated inflammatory response is effected through apoptosis of the neutrophils. When PMNs were exposed to dextran in whole blood samples, significant apoptosis was demonstrated. By these effects, human PMN survival was found to decrease [30]. Inflammatory mediators also modulate PMN survival. IL-8 plays a major role in the markedly reduced rate of programmed cell death of neutrophils after CPB [31]. In the present investigation we have demonstrated the attenuation of IL-8 release by dextran-70. The free radical scavenger effect of dextran is also well known [8]. This action may contribute to the reduction of endothelial activation and injury after CPB, as clearly demonstrated in our investigation.  From the good predictive value of procalcitonin [6] and its blunted kinetics in the dextran-treated group in our study, one can suppose that dextran-70 may influence the patients' outcome after CPB. Further large-scale studies are required to confirm this assumption.  In our investigation a similarly blunted peak level of IL-8 was found after dextran-70 administration as that reported earlier by Wan and colleagues on coronary patients operated on without CPB [32]. IL-8 plays an important role in the formation of the myocardial and pulmonary ischaemia-reperfusion injury developing after the use of CPB [3,7,33]. Its serum concentration correlates with postoperative cTr-I values [33]. The peak plasma IL-8 level also correlates with the magnitude of the proximal tubular injury following CABG surgery [34]. On the basis of our results, a lower IL-10 peak concentration occurred proportionally with the IL-8 peak level when dextran infusion was used, which indicates that no imbalance developed between proinflammatory and anti-inflammatory responses. High doses of aprotinin or a heparin-coated CPB tubing set also reduce IL-10 production following CPB [33,35]. Steroids increase the concentration of IL-10 with the consequences of immune suppression [35,36].  We found no significant action of dextran-70 on the levels of C-reactive protein, IL-6 and IL-6r, but the peak concentration of IL-6 and C-reactive protein was lower and that of IL-6r was higher in the group administered dextran. Previous investigations proved that IL-6 [33,37] and C-reactive protein [2] levels did not differ in CABG and off-pump coronary artery bypass surgery, but reduced IL-6 levels occurred after minimally invasive direct coronary artery bypass surgery, which suggests that operative trauma itself rather than CPB or ischaemia-reperfusion injury initiates the release of these factors [2]. These results suggest that dextran can reduce the inflammation resulted from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma.  There is an increasing body of evidence that the damaging effect of ischaemia-reperfusion in the heart is related to inflammatory processes [3] and that attenuation of the inflammatory response improves myocardial outcome following cardiac surgery [36]. The pattern of cardiac cTr-I release is similar after CABG and after valve surgery, but off-pump coronary artery bypass surgery results in less elevation than CABG using CPB [38]. Troponin-I release was reduced in the patient group where dextran-70 was applied, which may indicate that dextran-70 decreases the ischaemia-reperfusion injury after cardiac operation. The difference in cTr-I was rather small between the two groups, and therefore its clinical relevance must be confirmed in a large-scale study.  In our investigation dextran infusion has increased the stroke volume index independently of the preload by the reduction of the systemic vascular resistance index. Although the intrathoracic blood volume index and stroke volume variation did not differ between the groups it cannot be excluded that the observed differences in haemodynamics are partly due to the different volume effects of dextran and gelatin – whereas on the basis of our sELAM-1 and soluble ICAM-1 results, dextran infusion reduces the degree of the endothelial damage and activation. Particularly high preoperative sELAM-1 plasma concentration figures were found in the dextran group in contrast to the control group, indicating higher preoperative endothelial dysfunction among these patients. The levels of sELAM-1 and ICAM-1 significantly increased in the control group, but did not change in those patients who received dextran. This effect on the activation and damage of the endothelium may explain dextran's favourable influence on the vasomotor regulatory disturbance. Cardiopulmonary bypass alters vasomotor regulation, reducing the endothelium-dependent relaxation [39]. The nitric oxide production is significantly reduced up to 6 hours after CPB [40], which coincides with the time interval where the main difference in the SVRI was found in our study.  For the statistical analysis, six series of observations were represented over time to show the haemodynamic status at every examined timepoint of the inflammatory mediators. Using Bonferroni correction for multiple comparison, these many timepoints have resulted in a very high correction factor, increasing the possible statistical error, which may mask real differences. Although the observed statistical power was high, particularly in case of the SVRI, the clinical relevance of these finding must be justified in a study investigating a larger population.  The administration of HES 130/0.4 has also been investigated on the inflammatory response in other patient populations (for example, in patients undergoing major abdominal surgery). The IL-6, IL-8 and soluble ICAM-1 release was found to be lower in the HES-treated group, but the concentration of sELAM-1 was similar in the HES-treated and in the lactated Ringer's solution-treated groups [20]. Although HES does possesses anti-inflammatory properties [17,18], as the authors concluded these results were probably due to differences in microcirculation, because crystalloid-based volume therapy may worsen the microcirculatory blood flow and tissue oxygenation despite sufficient haemodynamic conditions [41]. The microhaemodynamic status was not measured in our investigation, but previously gelatin had been shown to increase cerebral blood flow velocity and to improve cutaneous microcirculation, more expressively than HES, during haemodilution (to a haematocrit level of 30.0%). That effect on microcirculation was related inversely to haematocrit, which means that after autologue blood retransfusion the parameters of cutaneous microcirculation have worsened [42]. Similarly to dextran, in our investigation HES was shown to diminish the endothelial activation or damage in critically ill patients. The soluble ICAM-1 and sELAM-1 levels did not increase following HES administration compared with the increase of these molecular levels in the control group treated with human albumin (20%).  On the basis of comparative animal experiments investigating the effects of colloids on leukocyte-endothelial interaction we have investigated the presumably most effective colloid, dextran-70, during CPB and we have proved its anti-inflammatory effect. Having said that, questions still remain of whether dextran has any advantage over other colloids in the anti-inflammatory properties in clinical situations, and whether it results in real clinical benefit on patient outcome. Further clinical studies are required to compare the anti-inflammatory effect of dextran with that of HES, and large-scale clinical studies must justify that the reduction of inflammation by dextran can be translated into clinical benefit. Another question to be raised is whether dextran administrated in a microdose is, or is not, able to reduce the inflammation in clinical situations of systemic inflammatory response syndrome, as in experimental studies [8], because microdose administration eliminates the antihaemostatic effects.  Blood loss was higher in the dextran group than the control group, which can be explained by the higher antihaemostatic potential. This difference, however, is surprisingly not clinically significant, since the number of red blood cell transfusions and haematocrit levels did not differ.  The limitation of this study is that gelatin, or any other colloid, administrated in the control group cannot be considered neutral concerning the inflammatory response. An infusion possessing anti-inflammatory effects is more acceptable for the control group than an infusion with proinflammatory features. Although gelatin administration did not influence neutrophil infiltration, NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity in a septic model [17], a moderate favourable effect on inflammation was indicated, reducing the Ba fragment of the complement cascade [24] and impairing the firm leukocyte adhesion in an in vitro model [23]. Certain albumin batches possess well-documented proinflammatory actions (for example, activating E-selectin, ICAM-1, vascular cell adhesion molecule 1), which seriously question the relevance of human albumin as a valid control for studies concerning inflammation [43]. Also, the use of lactated Ringer infusion is associated with significant neutrophil activation [44] and early expression of endothelial E-selectin and P-selectin [45]. Another limitation of this study is the single institutional setting. There were no differences in morbidity, mortality or length of intensive care unit stay between the groups but the low number of patients in our study does not allow one to conclude on the clinical outcome parameters.BODY.CONCLUSION:To the best of our knowledge our investigation is the first to show that dextran-70 reduces the inflammatory cytokine response, the liberation of some soluble adhesion molecules and the peak level of procalcitonin following cardiac operations. These results suggest that dextran can reduce the inflammation resulting from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma. Further large-scale clinical studies are required to demonstrate this effect on patient outcome after cardiac surgery.BODY.KEY MESSAGES:• Dextran-70 reduces the inflammatory activation after CPB.BODY.ABBREVIATIONS:AVR = aortic valve replacement; CABG = coronary artery bypass grafting; CPB = cardiac surgery on cardiopulmonary bypass; cTr-I = cardiac troponin I; ELISA = enzyme-linked immunosorbent assay; HES = hydroxyethyl starches; ICAM-1 = intercellular adhesion molecule-1; IL = interleukin; NF = nuclear factor; PMN = polymorphonuclear leukocyte; sELAM-1 = soluble endothelial leukocyte adhesion molecule-1; SVRI = systemic vascular resistance index; TNF = tumour necrosis factor.BODY.COMPETING INTERESTS:The authors declare that they have no competing interests.BODY.AUTHORS' CONTRIBUTIONS:KG conceived the study, participated in the design, coordination, measurements and acquisition of data, performed the statistical analysis, drafted the manuscript and obtained sponsorship. AB made a substantial contribution to the execution of the study and acquisition of data. NA and LB made a substantial contribution to the design of the study, interpretation of the data and provided critical review of the manuscript. NA participated in the coordination of the study. GK participated in the study design and helped to write the manuscript. VG and JG carried out the immunoassays, discussed the results and provided a critical review of the manuscript. TK carried out laboratory measurements, discussed the results and provided a critical review of the manuscript. All authors read and approved the final manuscript.\", \"TITLE: Influence of dextran-70 on systemic inflammatory response and myocardial ischaemia-reperfusion following cardiac operationsABSTRACT.INTRODUCTION:Experimental studies have demonstrated that dextran-70 reduces the leukocyte–endothelium interaction, but clinical evidence is still lacking. Our objective was to justify the anti-inflammatory effect of dextran-70 following cardiac operations.ABSTRACT.METHODS:Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20). The plasma concentration of procalcitonin, C-reactive protein, IL 6, IL 6r, IL 8, IL 10, soluble endothelial leukocyte adhesion molecule-1, soluble intercellular adhesion molecule-1, cardiac troponin-I and various haemodynamic parameters were measured in the perioperative period. Multivariate methods were used for statistical analysis.ABSTRACT.RESULTS:In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found. There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups. Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.ABSTRACT.CONCLUSION:Our investigation demonstrated that the use of dextran-70 reduces the systemic inflammatory response and cardiac troponin-I release following cardiac operation.ABSTRACT.TRIAL REGISTRATION NUMBER:ISRCTN38289094.BODY.INTRODUCTION:Cardiac surgery on cardiopulmonary bypass (CPB) results in a complex immune response characterized by the activation of all inflammatory pathways and strongly related to increased postoperative morbidity and mortality. The immune activation due to systemic inflammatory response syndrome exposes the patient to postoperative wound healing complications and to the development of infections [1,2].  Increased levels of the proinflammatory cytokines IL-6 and IL-8 play a major role in the pathogenesis of ischaemia-reperfusion injury [3] and multiple organ dysfunction syndrome [4]. IL-8 is a crucial chemokine, which attracts and activates polymorphonuclear leukocytes (PMNs) as well as T lymphocytes, and controls their migration. Tissue penetration, free radical production, and granulocyte elastase synthesis and release are also increased in PMNs [4]. Serum procalcitonin is a sensitive marker for the early detection of systemic inflammatory response syndrome [5]. Procalcitonin levels above 2 ng/ml are predictive for postoperative complications after cardiac operations [6]. Owing to inflammation, soluble adhesion molecules are shed into the circulation and their concentration correlates with the magnitude of endothelial activation and injury [1,7].  Several investigations have demonstrated that artificial colloids modulate the inflammatory response. Animal experiments have confirmed that dextran decreases the endothelial adhesion of PMNs in the postischaemic phase independently of the haemodilution [8]. Among trauma patients, dextran administration counteracts monocyte dysfunction and the related imbalance between coagulation and fibrinolysis [9]. Hypertonic saline dextran suppressed myocardial TNF-α, IL-1β and IL-6 secretion after an initial burn injury in an animal study, improving ventricular performance after subsequent septic challenge [10]. Experimental and clinical studies have justified the beneficial effects of dextran in the prevention of acute respiratory distress syndrome following trauma and sepsis [11], radiation injury [12], pancreatitis [13] and lower limb reperfusion injury [14].  It has been reported that hydroxyethyl starches (HES) reduce capillary leakage [15], leading to the concept of 'plugging the leaks' in various diseases, including sepsis and burns [16]. In a polymicrobial sepsis model, HES inhibited the inflammatory cytokine response, neutrophil infiltration and expression of intercellular adhesion molecule-1 (ICAM-1) mRNA [17]. Other anti-inflammatory manifestations of low-molecular-weight HES include impaired neutrophil respiratory burst and reduced neutrophil chemotaxis [18]. Administration of HES was associated with reduced markers of inflammation and endothelial activation in sepsis [19] and in patients undergoing major abdominal surgery [20].  Without any evidence of modulating the inflammatory response, gelatin infusion has been considered pharmacologically inert [21]. This assumption was confirmed in an experimentally induced acute lung injury model, where the inflammatory response (TNF-α) and oxidative stress were not affected by gelatin [22]. A recently published investigation has also indicated that NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity were not affected by modified fluid gelatin in a polymicrobial sepsis model [17] – whereas, like other artificial colloids, gelatin impairs firm leukocyte adhesion to the endothelium in vitro [23], and applied in the priming fluid gelatin reduces the contact activation of complement cascades by binding to fragment Ba [24]. Nevertheless an increased TNF-α release was demonstrated after the incubation of blood with gelatin in vitro [25], but in vivo investigation has revealed that gelatin does not alter PMN function [26].  Despite numerous studies having been published concerning the influence of colloids on inflammation, only few comparative studies exist. Reducing the endothelial adhesion of PMNs, dextran was reported to be more potent than HES in leukocyte-related reperfusion injury, and in contrast to HES the anti-inflammatory effect of dextran developed even in nondilutional microdose administration [8].  On the basis of experimental data it may be hypothesized that dextran attenuates the inflammatory response following cardiac surgery. There are, however, no exact clinical data in the literature that would support the anti-inflammatory effect of dextran following cardiac surgery. Our objective was the investigation of the effects of dextran-70 compared with gelatin as a control, on the levels of serum procalcitonin, on the inflammatory cytokine response, the markers of endothelial damage, myocardial ischaemia-reperfusion injury and haemodynamics after CPB. Our hypothesis was that administration of dextran reduces the level of inflammatory mediators and cardiac troponin-I (cTr-I) at the most important timepoints.BODY.MATERIALS AND METHODS:With permission from the ethical committee of the hospital, 40 patients undergoing elective first-time CPB – 32 patients undergoing coronary artery revascularization (coronary artery bypass grafting (CABG)), eight patients undergoing aortic valve replacement (AVR) – were involved in this prospective, randomized, double-blind study after individual consent was obtained. The setting of the study was single institutional. Two experienced anaesthesiologists and two experienced surgeons were involved in the study. Exclusion criteria were as follows: 'redo' operation, hepatic disease, renal dysfunction, immunologic disease, steroid treatment, intake of aspirin or other cyclooxygenase inhibitor within 7 days prior to surgery, or known allergy to volume expanders used in the study. None of the patients received volatile anaesthetics, steroids or aprotinin and haemofiltration was not used either. No shed mediastinal blood was retransfused during the postoperative period.  Two groups were formed following computerized randomization. Twenty patients (CABG, 17 patients; AVR, three patients) were given dextran-70 (6%; average molecular weight 70,000 Da) infusion (Macrodex; Pharmalink, Inc., Upplands Väsby, Sweden) (group A), while in the control group 20 patients (CABG, 15 patients; AVR, five patients) were given oxypolygelatin (5.5%; average molecular weight 30,000 Da) infusion (Gelifundol; Biotest Pharma, Inc., Dreieich, Germany) (group B). Following the induction of anaesthesia, artificial colloid was administered using infusion pumps (Model 591; IVAC, Inc., San Diego, CA, USA). After the application of hapten inhibition by 20 ml dextran-1 (Promit; Fresenius Kabi, Inc., Norge AS, Norway), dextran-70 infusion was used at the dose of 7.5 ml/kg for 30 minutes before CPB, and at a dose of 12.5 ml/kg for 14 hours following the cessation of CPB. Gelatin was infused by the same body-weight-based volume as dextran. The indication of the colloid administration was volume substitution. Depending on the actual haemodynamic and volume status, crystalloid infusion was administered together with a fixed dose of colloid.  Anaesthesia was carried out by a standardized total intravenous method. Premedication was achieved with midazolam. For the induction of anaesthesia, midazolam, propofol in a target controlled infusion perfusion device using DiprifusorTM (Alaris Medical Systems, Hampshire, UK), alfentanil and pipecuronium were used, while propofol (target controlled infusion) and alfentanil were given to maintain anaesthesia. Anticoagulation was maintained with heparin (initial value 300 IU/kg) to keep the activated clotting time longer than 400 seconds. Protamine was administered in a 1:1 ratio based on the initial heparin bolus (necessary to achieve the target activated clotting time). Cardiopulmonary bypass was carried out in normothermia, with the use of a roller pump (Cobe Cardiovascular, Inc., Arvada, Colorado USA), with pulsatile flow rate of 2.4 l/min/m2 and a membrane oxygenator (AffinityTM NT 541; Medtronic, Inc., Minneapolis, MN, USA). Antegrade, cold, crystalloid cardioplegia (modified Bretschneider solution) injected into the aortic root was used for myocardial protection. The Pulsion PiCCOTM (Pulsion Medical Systems, Inc., München, Germany) device was used for haemodynamic monitoring.  Packed red blood cell administration was applied when the haemoglobin level was less then 90 g/l, or during CPB when haemoglobin was below 70 g/l. Postoperative complications were defined as follows: cardiovascular complication (low cardiac output with cardiac index <2.2 l/min/m2 after volume infusion, requiring the use of positive inotrop agents and/or intraaortic balloon pump); perioperative myocardial infarction with typical electrocardiogram changes and creatine kinase MB >75 U/ml (three times the upper limit of the reference range); acute lung injury (prolonged ventilation, PaO2/FiO2 ratio <200); acute renal failure (serum creatinine >230 μmol/l); neurologic complications (stroke, ischaemic insults); gastrointestinal complications (ischaemia, bleeding); and infections.  Arterial blood samples were taken from the indwelling femoral artery cannula at the following time intervals: t1, before anaesthesia; t2, 10 minutes after CPB; t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; and t6, 44 hours after CPB. At the same timepoints, the following haemodynamic parameters were registered: heart rate, arterial blood pressure, cardiac index, stroke volume index, stroke volume variation, systemic vascular resistance index (SVRI), intrathoracic blood volume index, and extravascular lung water index. The haematocrit (packed cell volume), haemoglobin and blood cell count were measured at all time intervals. Determination of the plasma concentration of inflammatory mediators – interleukins (IL-6, IL-6r, IL-8, IL-10) and soluble adhesion molecules (soluble endothelial leukocyte adhesion molecule-1 (sELAM-1), soluble ICAM-1) – was carried out by ELISA (DIACLONE ResearchTM, Besançon, France) complying with the technologic regulations of the manufacturer. Blood samples were centrifuged with a cooled centrifuge at 1,000 × g for 15 minutes. Centrifuged plasma was stored at -86°C.  Three plasma samples were analysed for cytokine and soluble adhesion molecule levels with the sampling timepoints based on the kinetics of the single mediators according to the data in the literature. In each case the first measurement point was the preoperative control value, the second was the expected maximal value of the given mediator after cardiac surgery, while the third measurement point was the value corresponding to the dropoff phase [1,7]. The t1, t3 and t4 samples were analysed for IL-6 and IL-6r, while for IL-8 and IL-10 determinations the t1, t2, and t3 samples were used. Monitoring of the adhesion molecules was done as follows: sELAM-1 at the t1, t4 and t5 timepoints, and soluble ICAM-1 as the t1, t5 and t6 samples. The average of the duplicated ELISA test results was corrected using the following equation: corrected concentration = noncorrected concentration × actual plasma fraction/plasma fraction of the t1 sample. Procalcitonin was measured using an immunoluminometric assay (reference range 0–0.5 ng/ml; LUMItestTM; BRAHMS GmbH, Berlin, Germany). For the measurement of serum C-reactive protein the immune turbidimetric method was used (reference range 0–10 mg/l; DIALABTM, Vienna, Austria). cTr-I was measured by a two-site immunoluminometric assay (reference range 0–0.03 ng/ml; LIAISONTM Troponin I; DiaSorin S.p.A, Saluggia, Italy). For procalcitonin measurements we used the t1 and t5 blood samples, while for C-reactive protein the t1, t5 and t6 samples were used, and for cTr-I the t1, t4, t5 and t6 samplings were used.BODY.MATERIALS AND METHODS.STATISTICAL ANALYSIS:Statistical analysis was performed by SPSS for Windows 9.0 software (SPSS Inc., Chicago, Illinois, USA). After obtaining the results for 22 patients a midterm analysis was performed to calculate the necessary total sample size – Altman's nomogram [27] was used after calculating the standardized difference of the inflammatory mediators, setting the statistical power at 80% and choosing a 5% significance level. In the case of IL-8, IL-10, ICAM-1 and procalcitonin, the standardized difference and the necessary sample size were (0.924) 36, (0.886) 39, (1.326) 19 and (1.041) 29, respectively. According to the midterm analysis the sample size was determined to be 40 patients.  For the comparison of the basic data, the chi-squared test and Student's t test were used. We checked the parameters for normal distribution by the Kolmogorov–Smirnov test. If the result proved significant, the nonparametric test was used consecutively. Among inflammatory markers and cTr-I, nonparametric methods were used (Kruskal–Wallis test, Friedman test); and for haemodynamic parameters the general linear model repeated-measurement analysis (analysis of variance) with Bonferroni adjustment for multiple comparison was used for the analysis of the intraindividual and interindividual differences. Any difference was regarded statistically significant if p < 0.05. The results are displayed in the form of the mean ± standard deviation, as the median (range), or as a box-plot where the median, 25–75% and 2.5–97.5% percentile ranges are depicted.BODY.RESULTS:Past medical and perioperative data of the two groups are presented in Table 1. No operative mortality, low cardiac output, lung injury, renal failure, neurological complications, gastrointestinal complications, surgical intraoperative problems or wound healing problems occurred among the patients involved in the study. Myocardial infarction had developed in three cases, one case in group A and two cases in group B. Positive inotrope drug was not applied after the operation, and no differences were found in the frequency of vasodilator therapy (p = 0.584) or β-blocker therapy (p = 0.333) between the groups. The total postoperative mediastinal and pleural drainage proved to be higher in group A. Nevertheless, the amount of the transfused red blood cell units did not differ between the two groups. There was also no significant difference between the preoperative and the 44-hour postoperative haematocrit values, which indicates that the red blood cell loss was approximately the same in both groups.   Table 1 Anamnestic and perioperative data Group A Group B p  value a Age (years) 61.1 ± 6.5 62.5 ± 7.6 0.535 Gender (male/female) 13/7 14/6 0.736 Body mass index (kg/m 2 ) 28.7 ± 3.9 28.9 ± 3.8 0.821 Hypertension (%) 47.2 52.8 0.292 Diabetes mellitus (type I/type II/impaired glucose tolerance) (%) 2/4/1 2/3/1 0.733 Preoperative ejection fraction (%) 55.6 ± 12.6 56.1 ± 9.7 0.906 EuroScore (log) (%) 2.5 ± 1.2 2.9 ± 1.4 0.405 Amount of plasma substitute (ml) 1626 ± 212 1606 ± 205 0.725 Amount of crystalloids (ml) 4172 ± 660 4107 ± 665 0.765 Number of anastomoses (coronary artery bypass graft) 3.5 ± 1.0 3.5 ± 0.9 0.991 Aortic Xclamp (min) 53 ± 13.8 59 ± 18.1 0.403 Cardiac surgery on cardiopulmonary bypass duration (min) 83 ± 23.7 90 ± 29.3 0.401 Operation time (min) 249 ± 64.5 258 ± 61.7 0.634 Minimum rectal temperature (°C) 34.8 ± 0.6 35.0 ± 0.5 0.274 Preoperative packed cell volume 0.40 ± 0.034 0.39 ± 0.040 0.723 Postoperative 44 hours packed cell volume 0.30 ± 0.035 0.30 ± 0.035 0.623 Postoperative drainage (44 hours, ml) 818 ± 286 588 ± 179 0.005 Red blood cell transfusion (U) 1.8 ± 1.3 1.6 ± 1.2 0.548 Extubation time (hours) 9.2 ± 4.1 9.3 ± 4.6 0.894 Intensive care unit stay (hours) 54 ± 23 47 ± 6 0.209 Hospital stay (days) 9.9 ± 2.4 8.9 ± 1.3 0.114 Data presented as the mean ± standard deviation.  a Chi-squared test or Student's  t  test.   The peak level of procalcitonin was lower in group A (Figure 1.). The procalcitonin level was below 2 ng/ml for all of the patients in group A, but it increased in 40% of the patients in group B with a peak level higher than 2 ng/ml (P = 0.001). IL-8 level elevation was moderate in group A in contrast to the increase experienced in the control group, which is a well-known characteristic of CPB. The between-group difference in IL-8 was significant after CPB (Figure 2). The same kinetics were found for IL-10 (Table 2). The preoperative concentration of sELAM-1 was higher in group A, and did not increase any further, in contrast to the control group that started at a low preoperative value and subsequently rose significantly (Table 2). The level of soluble ICAM-1 did not show any increase in group A. On the contrary, there was a significant and characteristic increase in the control group. The between-group differences for soluble ICAM-1 were significant after CPB (Figure 3). No significant difference was found in C-reactive protein, IL-6 or IL6r between the groups. The cTr-I levels were lower in group A, especially at the t5 timepoint (Table 2).  Table 2 Results of the inflammatory mediators and cardiac troponin I t1 t2 t3 t4 t5 t6 p C-reactive protein (mg/l) \\u2003Group A 3.7 (1.0–22.6) 79.9 (50.0–131.7) 112.0 (61.1–177.6) <0.001 † \\u2003Group B 2.6 (0.6–10.5) 87.6 (52.4–143.0) 131.0 (71.0–228.0) <0.001 † p  = 0.068* p  = 0.092* p  = 0.168* IL-6 (pg/ml) \\u2003Group A 1.6 (0.4–21.8) 95.0 (13.6–405.1) 46.3 (16.1–149.5) <0.001 † \\u2003Group B 2.0 (0.4–60.6) 130.5 (21.7–353.8) 49.2 (14.8–214.5) <0.001 † p  = 0.107* p  = 0.829* p  = 0.482* IL-6r (ng/ml) \\u2003Group A 43.6 (1.7–125.0) 47.4 (0.7–109.5) 56.2 (25.2–226.3) 0.949 † \\u2003Group B 40.7 (15.6–94.6) 42.4 (22.2–100.5) 50.2 (13.2–104.9) 0.861 † p  = 0.607* p  = 0.914* p  = 0.304* IL-10 (pg/ml) \\u2003Group A 1.9 (0.2–24.0) 47.2 (2.3–476.6) 7.2 (1.3–90.9) <0.001 † \\u2003Group B 2.6 (0.8–9.7) 209.7 (16.3–814.3) 56.1 (3.6–225.1) <0.001 † p  = 0.136* p  = 0.001* p  = 0.001* Soluble endothelial leukocyte adhesion molecule-1 (ng/ml) \\u2003Group A 88.6 (49.8–194.5) 88.5 (14.4–189.6) 72.7 (8.9–163.1) 0.058 † \\u2003Group B 49.0 (18.3–144.1) 130.7 (33.0–360.7) 72.6 (16.7–224.7) <0.001 † p  < 0.001* p  = 0.033* p  = 0.957* Cardiac troponin-I (ng/ml) \\u2003Group A 0.02 (0.01–0.022) 0.22 (0.07–0.85) 0.13 (0.03–0.75) <0.001 † \\u2003Group B 0.01 (0.01–0.016) 0.66 (0.10–1.28) 0.19 (0.03–0.80) <0.001 † p  = 0.520* p  = 0.018* p  = 0.097* Data presented as the median (range). t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  † Intraindividual differences (Friedman test), *between-group differences (Kruskal–Wallis test).   Figure 1Procalcitonin plasma levels before operation and 24 hours after cardiopulmonary bypass. Procalcitonin (PCT) plasma levels in the treated and control groups, before operation (t1) and 24 hours after cardiopulmonary bypass (t5). Significant elevation was found in both groups (*Friedman tests). After the operation, procalcitonin was lower in group A. The between-group difference was significant (+ Kruskal–Wallis test).  Figure 2IL-8 plasma levels before operation and after cardiopulmonary bypass. IL-8 plasma levels in the treated and control groups, before operation (t1) and 10 minutes (t2) and 2 hours (t3) after cardiopulmonary bypass. Significant elevation was found in both groups (*Friedman tests). At t2 and t3 the IL-8 plasma levels were lower in group A. The between-group differences were significant (+Kruskal–Wallis test).  Figure 3Soluble intercellular adhesion molecule 1 plasma levels before operation and after cardiopulmonary bypass. Soluble intercellular adhesion molecule 1 (ICAM-1) plasma levels in the treated and control groups, before operation (t1) and 24 hours (t5) and 44 hours (t6) after cardiopulmonary bypass. No elevation was found in group A, but the elevation was significant in group B (*Friedman tests). The between-group differences were significant after cardiac surgery on cardiopulmonary bypass (+Kruskal–Wallis test).  No difference was found between CABG and AVR patients in the inflammatory markers or cTr-I, except for ICAM-1 in group B, which was higher among AVR patients before operation (p = 0.047) and at the 24-hour timepoint (p = 0.023).  Patients with postoperative atrial fibrillation or pacemaker rhythm in the VVI mode (group A, five patients; group B, four patients) were excluded from the analysis of haemodynamic data. The cardiac index and stroke volume index were higher while the SVRI figures were lower in group A, with an observed statistical power of 83%. The intrathoracic blood volume index, stroke volume variation, heart rate, arterial blood pressure (systolic) (p = 0.787), arterial blood pressure (diastolic) (p = 0.771) and extravascular lung water index (p = 0.326) did not differ between the two groups (Table 3).  Table 3 Results of the haemodynamic data t1 t2 t3 t4 t5 t6 p  value a Heart rate (l/min) 0.925 \\u2003Group A 60 ± 12 76 ± 14 78 ± 13 84 ± 18 84 ± 7 92 ± 10 \\u2003Group B 59 ± 8 72 ± 9 78 ± 12 81 ± 12 87 ± 12 97 ± 12 Stroke volume index (ml/m 2 ) 0.026 \\u2003Group A 38.5 ± 6.5 33.5 ± 9.1 31.9 ± 8.2 32.8 ± 9.0 36.9 ± 13.8 36.1 ± 7.4 \\u2003Group B 36.4 ± 5.7 30.2 ± 5.8 27.6 ± 8.0 27.6 ± 7.5 31.3 ± 10.0 30.1 ± 5.0 Cardiac index (l/min/m 2 ) 0.010 \\u2003Group A 2.3 ± 0.45 2.4 ± 0.39 2.4 ± 0.63 2.7 ± 0.63 3.0 ± 0.98 3.4 ± 0.94 \\u2003Group B 2.2 ± 0.36 2.2 ± 0.31 2.0 ± 0.41 2.2 ± 0.44 2.6 ± 0.38 2.9 ± 0.49 Stroke volume variation (%) 0.873 \\u2003Group A 1.5 ± 0.8 2.3 ± 3.3 3.4 ± 5.3 2.2 ± 1.8 4.5 ± 11.5 2.0 ± 0.7 \\u2003Group B 2.6 ± 3.9 3.1 ± 2.9 4.9 ± 8.5 2.8 ± 3.1 2.5 ± 1.5 2.5 ± 1.0 Intrathoracic blood volume index (ml/m 2 ) 0.387 \\u2003Group A 861 ± 132 829 ± 129 875 ± 120 882 ± 122 923 ± 137 975 ± 136 \\u2003Group B 845 ± 153 811 ± 151 831 ± 192 831 ± 169 871 ± 128 919 ± 214 Systemic vascular resistance index (dyn s/cm 5  m 2 ) 0.005 \\u2003Group A 2,663 ± 414 2,031 ± 492 2,701 ± 604 † 2,418 ± 534 2,076 ± 514 2,052 ± 430 \\u2003Group B 2,732 ± 424 2,279 ± 428 3,499 ± 964 2,902 ± 659 2,470 ± 505 2,227 ± 507 Data presented as the mean ± standard deviation. t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  a Between-group differences, general linear model repeated measurement analysis (analysis of variance).  † p  < 0.05 (with Bonferroni adjustment for multiple comparison).BODY.DISCUSSION:For the first time according to the literature, we have shown in the present investigation that dextran-70 reduces the inflammatory cytokine response, reduces the peak levels of serum procalcitonin and reduces the peak levels of the markers of endothelial activation or damage during the inflammatory activation following CPB. Earlier investigation had indicated that dextran-70 reduces complement-3 activation product levels during cardiopulmonary bypass [28], but subsequently it was revealed that fresh frozen plasma, which was applied in the control group in large volume, contains a high level of complement-3 [29].  The exact mechanism of the anti-inflammatory effect of dextran is still unclear. Intravital studies on haemodilution in controlled ischaemia have shown that dextran reduces leukocyte adhesion onto the endothelium. The inhibition of leukocyte–endothelium interaction already occurs in the pharmacological microdose of dextran, independently of the haemodilution effect [8]. On the basis of recently published experimental data, dextran inhibits neutrophil adhesion by a neutrophil-dependent mechanism, regulating integrin function rather than interfering with endothelial cell activation [23]. In the same experimental setting, gelatin represented a similar effect on neutrophil adhesion to that of dextran; therefore, it can be supposed that other mechanisms should also be of importance. The termination of a neutrophil-mediated inflammatory response is effected through apoptosis of the neutrophils. When PMNs were exposed to dextran in whole blood samples, significant apoptosis was demonstrated. By these effects, human PMN survival was found to decrease [30]. Inflammatory mediators also modulate PMN survival. IL-8 plays a major role in the markedly reduced rate of programmed cell death of neutrophils after CPB [31]. In the present investigation we have demonstrated the attenuation of IL-8 release by dextran-70. The free radical scavenger effect of dextran is also well known [8]. This action may contribute to the reduction of endothelial activation and injury after CPB, as clearly demonstrated in our investigation.  From the good predictive value of procalcitonin [6] and its blunted kinetics in the dextran-treated group in our study, one can suppose that dextran-70 may influence the patients' outcome after CPB. Further large-scale studies are required to confirm this assumption.  In our investigation a similarly blunted peak level of IL-8 was found after dextran-70 administration as that reported earlier by Wan and colleagues on coronary patients operated on without CPB [32]. IL-8 plays an important role in the formation of the myocardial and pulmonary ischaemia-reperfusion injury developing after the use of CPB [3,7,33]. Its serum concentration correlates with postoperative cTr-I values [33]. The peak plasma IL-8 level also correlates with the magnitude of the proximal tubular injury following CABG surgery [34]. On the basis of our results, a lower IL-10 peak concentration occurred proportionally with the IL-8 peak level when dextran infusion was used, which indicates that no imbalance developed between proinflammatory and anti-inflammatory responses. High doses of aprotinin or a heparin-coated CPB tubing set also reduce IL-10 production following CPB [33,35]. Steroids increase the concentration of IL-10 with the consequences of immune suppression [35,36].  We found no significant action of dextran-70 on the levels of C-reactive protein, IL-6 and IL-6r, but the peak concentration of IL-6 and C-reactive protein was lower and that of IL-6r was higher in the group administered dextran. Previous investigations proved that IL-6 [33,37] and C-reactive protein [2] levels did not differ in CABG and off-pump coronary artery bypass surgery, but reduced IL-6 levels occurred after minimally invasive direct coronary artery bypass surgery, which suggests that operative trauma itself rather than CPB or ischaemia-reperfusion injury initiates the release of these factors [2]. These results suggest that dextran can reduce the inflammation resulted from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma.  There is an increasing body of evidence that the damaging effect of ischaemia-reperfusion in the heart is related to inflammatory processes [3] and that attenuation of the inflammatory response improves myocardial outcome following cardiac surgery [36]. The pattern of cardiac cTr-I release is similar after CABG and after valve surgery, but off-pump coronary artery bypass surgery results in less elevation than CABG using CPB [38]. Troponin-I release was reduced in the patient group where dextran-70 was applied, which may indicate that dextran-70 decreases the ischaemia-reperfusion injury after cardiac operation. The difference in cTr-I was rather small between the two groups, and therefore its clinical relevance must be confirmed in a large-scale study.  In our investigation dextran infusion has increased the stroke volume index independently of the preload by the reduction of the systemic vascular resistance index. Although the intrathoracic blood volume index and stroke volume variation did not differ between the groups it cannot be excluded that the observed differences in haemodynamics are partly due to the different volume effects of dextran and gelatin – whereas on the basis of our sELAM-1 and soluble ICAM-1 results, dextran infusion reduces the degree of the endothelial damage and activation. Particularly high preoperative sELAM-1 plasma concentration figures were found in the dextran group in contrast to the control group, indicating higher preoperative endothelial dysfunction among these patients. The levels of sELAM-1 and ICAM-1 significantly increased in the control group, but did not change in those patients who received dextran. This effect on the activation and damage of the endothelium may explain dextran's favourable influence on the vasomotor regulatory disturbance. Cardiopulmonary bypass alters vasomotor regulation, reducing the endothelium-dependent relaxation [39]. The nitric oxide production is significantly reduced up to 6 hours after CPB [40], which coincides with the time interval where the main difference in the SVRI was found in our study.  For the statistical analysis, six series of observations were represented over time to show the haemodynamic status at every examined timepoint of the inflammatory mediators. Using Bonferroni correction for multiple comparison, these many timepoints have resulted in a very high correction factor, increasing the possible statistical error, which may mask real differences. Although the observed statistical power was high, particularly in case of the SVRI, the clinical relevance of these finding must be justified in a study investigating a larger population.  The administration of HES 130/0.4 has also been investigated on the inflammatory response in other patient populations (for example, in patients undergoing major abdominal surgery). The IL-6, IL-8 and soluble ICAM-1 release was found to be lower in the HES-treated group, but the concentration of sELAM-1 was similar in the HES-treated and in the lactated Ringer's solution-treated groups [20]. Although HES does possesses anti-inflammatory properties [17,18], as the authors concluded these results were probably due to differences in microcirculation, because crystalloid-based volume therapy may worsen the microcirculatory blood flow and tissue oxygenation despite sufficient haemodynamic conditions [41]. The microhaemodynamic status was not measured in our investigation, but previously gelatin had been shown to increase cerebral blood flow velocity and to improve cutaneous microcirculation, more expressively than HES, during haemodilution (to a haematocrit level of 30.0%). That effect on microcirculation was related inversely to haematocrit, which means that after autologue blood retransfusion the parameters of cutaneous microcirculation have worsened [42]. Similarly to dextran, in our investigation HES was shown to diminish the endothelial activation or damage in critically ill patients. The soluble ICAM-1 and sELAM-1 levels did not increase following HES administration compared with the increase of these molecular levels in the control group treated with human albumin (20%).  On the basis of comparative animal experiments investigating the effects of colloids on leukocyte-endothelial interaction we have investigated the presumably most effective colloid, dextran-70, during CPB and we have proved its anti-inflammatory effect. Having said that, questions still remain of whether dextran has any advantage over other colloids in the anti-inflammatory properties in clinical situations, and whether it results in real clinical benefit on patient outcome. Further clinical studies are required to compare the anti-inflammatory effect of dextran with that of HES, and large-scale clinical studies must justify that the reduction of inflammation by dextran can be translated into clinical benefit. Another question to be raised is whether dextran administrated in a microdose is, or is not, able to reduce the inflammation in clinical situations of systemic inflammatory response syndrome, as in experimental studies [8], because microdose administration eliminates the antihaemostatic effects.  Blood loss was higher in the dextran group than the control group, which can be explained by the higher antihaemostatic potential. This difference, however, is surprisingly not clinically significant, since the number of red blood cell transfusions and haematocrit levels did not differ.  The limitation of this study is that gelatin, or any other colloid, administrated in the control group cannot be considered neutral concerning the inflammatory response. An infusion possessing anti-inflammatory effects is more acceptable for the control group than an infusion with proinflammatory features. Although gelatin administration did not influence neutrophil infiltration, NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity in a septic model [17], a moderate favourable effect on inflammation was indicated, reducing the Ba fragment of the complement cascade [24] and impairing the firm leukocyte adhesion in an in vitro model [23]. Certain albumin batches possess well-documented proinflammatory actions (for example, activating E-selectin, ICAM-1, vascular cell adhesion molecule 1), which seriously question the relevance of human albumin as a valid control for studies concerning inflammation [43]. Also, the use of lactated Ringer infusion is associated with significant neutrophil activation [44] and early expression of endothelial E-selectin and P-selectin [45]. Another limitation of this study is the single institutional setting. There were no differences in morbidity, mortality or length of intensive care unit stay between the groups but the low number of patients in our study does not allow one to conclude on the clinical outcome parameters.BODY.CONCLUSION:To the best of our knowledge our investigation is the first to show that dextran-70 reduces the inflammatory cytokine response, the liberation of some soluble adhesion molecules and the peak level of procalcitonin following cardiac operations. These results suggest that dextran can reduce the inflammation resulting from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma. Further large-scale clinical studies are required to demonstrate this effect on patient outcome after cardiac surgery.BODY.KEY MESSAGES:• Dextran-70 reduces the inflammatory activation after CPB.BODY.ABBREVIATIONS:AVR = aortic valve replacement; CABG = coronary artery bypass grafting; CPB = cardiac surgery on cardiopulmonary bypass; cTr-I = cardiac troponin I; ELISA = enzyme-linked immunosorbent assay; HES = hydroxyethyl starches; ICAM-1 = intercellular adhesion molecule-1; IL = interleukin; NF = nuclear factor; PMN = polymorphonuclear leukocyte; sELAM-1 = soluble endothelial leukocyte adhesion molecule-1; SVRI = systemic vascular resistance index; TNF = tumour necrosis factor.BODY.COMPETING INTERESTS:The authors declare that they have no competing interests.BODY.AUTHORS' CONTRIBUTIONS:KG conceived the study, participated in the design, coordination, measurements and acquisition of data, performed the statistical analysis, drafted the manuscript and obtained sponsorship. AB made a substantial contribution to the execution of the study and acquisition of data. NA and LB made a substantial contribution to the design of the study, interpretation of the data and provided critical review of the manuscript. NA participated in the coordination of the study. GK participated in the study design and helped to write the manuscript. VG and JG carried out the immunoassays, discussed the results and provided a critical review of the manuscript. TK carried out laboratory measurements, discussed the results and provided a critical review of the manuscript. All authors read and approved the final manuscript.\", \"TITLE: Influence of dextran-70 on systemic inflammatory response and myocardial ischaemia-reperfusion following cardiac operationsABSTRACT.INTRODUCTION:Experimental studies have demonstrated that dextran-70 reduces the leukocyte–endothelium interaction, but clinical evidence is still lacking. Our objective was to justify the anti-inflammatory effect of dextran-70 following cardiac operations.ABSTRACT.METHODS:Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20). The plasma concentration of procalcitonin, C-reactive protein, IL 6, IL 6r, IL 8, IL 10, soluble endothelial leukocyte adhesion molecule-1, soluble intercellular adhesion molecule-1, cardiac troponin-I and various haemodynamic parameters were measured in the perioperative period. Multivariate methods were used for statistical analysis.ABSTRACT.RESULTS:In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found. There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups. Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.ABSTRACT.CONCLUSION:Our investigation demonstrated that the use of dextran-70 reduces the systemic inflammatory response and cardiac troponin-I release following cardiac operation.ABSTRACT.TRIAL REGISTRATION NUMBER:ISRCTN38289094.BODY.INTRODUCTION:Cardiac surgery on cardiopulmonary bypass (CPB) results in a complex immune response characterized by the activation of all inflammatory pathways and strongly related to increased postoperative morbidity and mortality. The immune activation due to systemic inflammatory response syndrome exposes the patient to postoperative wound healing complications and to the development of infections [1,2].  Increased levels of the proinflammatory cytokines IL-6 and IL-8 play a major role in the pathogenesis of ischaemia-reperfusion injury [3] and multiple organ dysfunction syndrome [4]. IL-8 is a crucial chemokine, which attracts and activates polymorphonuclear leukocytes (PMNs) as well as T lymphocytes, and controls their migration. Tissue penetration, free radical production, and granulocyte elastase synthesis and release are also increased in PMNs [4]. Serum procalcitonin is a sensitive marker for the early detection of systemic inflammatory response syndrome [5]. Procalcitonin levels above 2 ng/ml are predictive for postoperative complications after cardiac operations [6]. Owing to inflammation, soluble adhesion molecules are shed into the circulation and their concentration correlates with the magnitude of endothelial activation and injury [1,7].  Several investigations have demonstrated that artificial colloids modulate the inflammatory response. Animal experiments have confirmed that dextran decreases the endothelial adhesion of PMNs in the postischaemic phase independently of the haemodilution [8]. Among trauma patients, dextran administration counteracts monocyte dysfunction and the related imbalance between coagulation and fibrinolysis [9]. Hypertonic saline dextran suppressed myocardial TNF-α, IL-1β and IL-6 secretion after an initial burn injury in an animal study, improving ventricular performance after subsequent septic challenge [10]. Experimental and clinical studies have justified the beneficial effects of dextran in the prevention of acute respiratory distress syndrome following trauma and sepsis [11], radiation injury [12], pancreatitis [13] and lower limb reperfusion injury [14].  It has been reported that hydroxyethyl starches (HES) reduce capillary leakage [15], leading to the concept of 'plugging the leaks' in various diseases, including sepsis and burns [16]. In a polymicrobial sepsis model, HES inhibited the inflammatory cytokine response, neutrophil infiltration and expression of intercellular adhesion molecule-1 (ICAM-1) mRNA [17]. Other anti-inflammatory manifestations of low-molecular-weight HES include impaired neutrophil respiratory burst and reduced neutrophil chemotaxis [18]. Administration of HES was associated with reduced markers of inflammation and endothelial activation in sepsis [19] and in patients undergoing major abdominal surgery [20].  Without any evidence of modulating the inflammatory response, gelatin infusion has been considered pharmacologically inert [21]. This assumption was confirmed in an experimentally induced acute lung injury model, where the inflammatory response (TNF-α) and oxidative stress were not affected by gelatin [22]. A recently published investigation has also indicated that NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity were not affected by modified fluid gelatin in a polymicrobial sepsis model [17] – whereas, like other artificial colloids, gelatin impairs firm leukocyte adhesion to the endothelium in vitro [23], and applied in the priming fluid gelatin reduces the contact activation of complement cascades by binding to fragment Ba [24]. Nevertheless an increased TNF-α release was demonstrated after the incubation of blood with gelatin in vitro [25], but in vivo investigation has revealed that gelatin does not alter PMN function [26].  Despite numerous studies having been published concerning the influence of colloids on inflammation, only few comparative studies exist. Reducing the endothelial adhesion of PMNs, dextran was reported to be more potent than HES in leukocyte-related reperfusion injury, and in contrast to HES the anti-inflammatory effect of dextran developed even in nondilutional microdose administration [8].  On the basis of experimental data it may be hypothesized that dextran attenuates the inflammatory response following cardiac surgery. There are, however, no exact clinical data in the literature that would support the anti-inflammatory effect of dextran following cardiac surgery. Our objective was the investigation of the effects of dextran-70 compared with gelatin as a control, on the levels of serum procalcitonin, on the inflammatory cytokine response, the markers of endothelial damage, myocardial ischaemia-reperfusion injury and haemodynamics after CPB. Our hypothesis was that administration of dextran reduces the level of inflammatory mediators and cardiac troponin-I (cTr-I) at the most important timepoints.BODY.MATERIALS AND METHODS:With permission from the ethical committee of the hospital, 40 patients undergoing elective first-time CPB – 32 patients undergoing coronary artery revascularization (coronary artery bypass grafting (CABG)), eight patients undergoing aortic valve replacement (AVR) – were involved in this prospective, randomized, double-blind study after individual consent was obtained. The setting of the study was single institutional. Two experienced anaesthesiologists and two experienced surgeons were involved in the study. Exclusion criteria were as follows: 'redo' operation, hepatic disease, renal dysfunction, immunologic disease, steroid treatment, intake of aspirin or other cyclooxygenase inhibitor within 7 days prior to surgery, or known allergy to volume expanders used in the study. None of the patients received volatile anaesthetics, steroids or aprotinin and haemofiltration was not used either. No shed mediastinal blood was retransfused during the postoperative period.  Two groups were formed following computerized randomization. Twenty patients (CABG, 17 patients; AVR, three patients) were given dextran-70 (6%; average molecular weight 70,000 Da) infusion (Macrodex; Pharmalink, Inc., Upplands Väsby, Sweden) (group A), while in the control group 20 patients (CABG, 15 patients; AVR, five patients) were given oxypolygelatin (5.5%; average molecular weight 30,000 Da) infusion (Gelifundol; Biotest Pharma, Inc., Dreieich, Germany) (group B). Following the induction of anaesthesia, artificial colloid was administered using infusion pumps (Model 591; IVAC, Inc., San Diego, CA, USA). After the application of hapten inhibition by 20 ml dextran-1 (Promit; Fresenius Kabi, Inc., Norge AS, Norway), dextran-70 infusion was used at the dose of 7.5 ml/kg for 30 minutes before CPB, and at a dose of 12.5 ml/kg for 14 hours following the cessation of CPB. Gelatin was infused by the same body-weight-based volume as dextran. The indication of the colloid administration was volume substitution. Depending on the actual haemodynamic and volume status, crystalloid infusion was administered together with a fixed dose of colloid.  Anaesthesia was carried out by a standardized total intravenous method. Premedication was achieved with midazolam. For the induction of anaesthesia, midazolam, propofol in a target controlled infusion perfusion device using DiprifusorTM (Alaris Medical Systems, Hampshire, UK), alfentanil and pipecuronium were used, while propofol (target controlled infusion) and alfentanil were given to maintain anaesthesia. Anticoagulation was maintained with heparin (initial value 300 IU/kg) to keep the activated clotting time longer than 400 seconds. Protamine was administered in a 1:1 ratio based on the initial heparin bolus (necessary to achieve the target activated clotting time). Cardiopulmonary bypass was carried out in normothermia, with the use of a roller pump (Cobe Cardiovascular, Inc., Arvada, Colorado USA), with pulsatile flow rate of 2.4 l/min/m2 and a membrane oxygenator (AffinityTM NT 541; Medtronic, Inc., Minneapolis, MN, USA). Antegrade, cold, crystalloid cardioplegia (modified Bretschneider solution) injected into the aortic root was used for myocardial protection. The Pulsion PiCCOTM (Pulsion Medical Systems, Inc., München, Germany) device was used for haemodynamic monitoring.  Packed red blood cell administration was applied when the haemoglobin level was less then 90 g/l, or during CPB when haemoglobin was below 70 g/l. Postoperative complications were defined as follows: cardiovascular complication (low cardiac output with cardiac index <2.2 l/min/m2 after volume infusion, requiring the use of positive inotrop agents and/or intraaortic balloon pump); perioperative myocardial infarction with typical electrocardiogram changes and creatine kinase MB >75 U/ml (three times the upper limit of the reference range); acute lung injury (prolonged ventilation, PaO2/FiO2 ratio <200); acute renal failure (serum creatinine >230 μmol/l); neurologic complications (stroke, ischaemic insults); gastrointestinal complications (ischaemia, bleeding); and infections.  Arterial blood samples were taken from the indwelling femoral artery cannula at the following time intervals: t1, before anaesthesia; t2, 10 minutes after CPB; t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; and t6, 44 hours after CPB. At the same timepoints, the following haemodynamic parameters were registered: heart rate, arterial blood pressure, cardiac index, stroke volume index, stroke volume variation, systemic vascular resistance index (SVRI), intrathoracic blood volume index, and extravascular lung water index. The haematocrit (packed cell volume), haemoglobin and blood cell count were measured at all time intervals. Determination of the plasma concentration of inflammatory mediators – interleukins (IL-6, IL-6r, IL-8, IL-10) and soluble adhesion molecules (soluble endothelial leukocyte adhesion molecule-1 (sELAM-1), soluble ICAM-1) – was carried out by ELISA (DIACLONE ResearchTM, Besançon, France) complying with the technologic regulations of the manufacturer. Blood samples were centrifuged with a cooled centrifuge at 1,000 × g for 15 minutes. Centrifuged plasma was stored at -86°C.  Three plasma samples were analysed for cytokine and soluble adhesion molecule levels with the sampling timepoints based on the kinetics of the single mediators according to the data in the literature. In each case the first measurement point was the preoperative control value, the second was the expected maximal value of the given mediator after cardiac surgery, while the third measurement point was the value corresponding to the dropoff phase [1,7]. The t1, t3 and t4 samples were analysed for IL-6 and IL-6r, while for IL-8 and IL-10 determinations the t1, t2, and t3 samples were used. Monitoring of the adhesion molecules was done as follows: sELAM-1 at the t1, t4 and t5 timepoints, and soluble ICAM-1 as the t1, t5 and t6 samples. The average of the duplicated ELISA test results was corrected using the following equation: corrected concentration = noncorrected concentration × actual plasma fraction/plasma fraction of the t1 sample. Procalcitonin was measured using an immunoluminometric assay (reference range 0–0.5 ng/ml; LUMItestTM; BRAHMS GmbH, Berlin, Germany). For the measurement of serum C-reactive protein the immune turbidimetric method was used (reference range 0–10 mg/l; DIALABTM, Vienna, Austria). cTr-I was measured by a two-site immunoluminometric assay (reference range 0–0.03 ng/ml; LIAISONTM Troponin I; DiaSorin S.p.A, Saluggia, Italy). For procalcitonin measurements we used the t1 and t5 blood samples, while for C-reactive protein the t1, t5 and t6 samples were used, and for cTr-I the t1, t4, t5 and t6 samplings were used.BODY.MATERIALS AND METHODS.STATISTICAL ANALYSIS:Statistical analysis was performed by SPSS for Windows 9.0 software (SPSS Inc., Chicago, Illinois, USA). After obtaining the results for 22 patients a midterm analysis was performed to calculate the necessary total sample size – Altman's nomogram [27] was used after calculating the standardized difference of the inflammatory mediators, setting the statistical power at 80% and choosing a 5% significance level. In the case of IL-8, IL-10, ICAM-1 and procalcitonin, the standardized difference and the necessary sample size were (0.924) 36, (0.886) 39, (1.326) 19 and (1.041) 29, respectively. According to the midterm analysis the sample size was determined to be 40 patients.  For the comparison of the basic data, the chi-squared test and Student's t test were used. We checked the parameters for normal distribution by the Kolmogorov–Smirnov test. If the result proved significant, the nonparametric test was used consecutively. Among inflammatory markers and cTr-I, nonparametric methods were used (Kruskal–Wallis test, Friedman test); and for haemodynamic parameters the general linear model repeated-measurement analysis (analysis of variance) with Bonferroni adjustment for multiple comparison was used for the analysis of the intraindividual and interindividual differences. Any difference was regarded statistically significant if p < 0.05. The results are displayed in the form of the mean ± standard deviation, as the median (range), or as a box-plot where the median, 25–75% and 2.5–97.5% percentile ranges are depicted.BODY.RESULTS:Past medical and perioperative data of the two groups are presented in Table 1. No operative mortality, low cardiac output, lung injury, renal failure, neurological complications, gastrointestinal complications, surgical intraoperative problems or wound healing problems occurred among the patients involved in the study. Myocardial infarction had developed in three cases, one case in group A and two cases in group B. Positive inotrope drug was not applied after the operation, and no differences were found in the frequency of vasodilator therapy (p = 0.584) or β-blocker therapy (p = 0.333) between the groups. The total postoperative mediastinal and pleural drainage proved to be higher in group A. Nevertheless, the amount of the transfused red blood cell units did not differ between the two groups. There was also no significant difference between the preoperative and the 44-hour postoperative haematocrit values, which indicates that the red blood cell loss was approximately the same in both groups.   Table 1 Anamnestic and perioperative data Group A Group B p  value a Age (years) 61.1 ± 6.5 62.5 ± 7.6 0.535 Gender (male/female) 13/7 14/6 0.736 Body mass index (kg/m 2 ) 28.7 ± 3.9 28.9 ± 3.8 0.821 Hypertension (%) 47.2 52.8 0.292 Diabetes mellitus (type I/type II/impaired glucose tolerance) (%) 2/4/1 2/3/1 0.733 Preoperative ejection fraction (%) 55.6 ± 12.6 56.1 ± 9.7 0.906 EuroScore (log) (%) 2.5 ± 1.2 2.9 ± 1.4 0.405 Amount of plasma substitute (ml) 1626 ± 212 1606 ± 205 0.725 Amount of crystalloids (ml) 4172 ± 660 4107 ± 665 0.765 Number of anastomoses (coronary artery bypass graft) 3.5 ± 1.0 3.5 ± 0.9 0.991 Aortic Xclamp (min) 53 ± 13.8 59 ± 18.1 0.403 Cardiac surgery on cardiopulmonary bypass duration (min) 83 ± 23.7 90 ± 29.3 0.401 Operation time (min) 249 ± 64.5 258 ± 61.7 0.634 Minimum rectal temperature (°C) 34.8 ± 0.6 35.0 ± 0.5 0.274 Preoperative packed cell volume 0.40 ± 0.034 0.39 ± 0.040 0.723 Postoperative 44 hours packed cell volume 0.30 ± 0.035 0.30 ± 0.035 0.623 Postoperative drainage (44 hours, ml) 818 ± 286 588 ± 179 0.005 Red blood cell transfusion (U) 1.8 ± 1.3 1.6 ± 1.2 0.548 Extubation time (hours) 9.2 ± 4.1 9.3 ± 4.6 0.894 Intensive care unit stay (hours) 54 ± 23 47 ± 6 0.209 Hospital stay (days) 9.9 ± 2.4 8.9 ± 1.3 0.114 Data presented as the mean ± standard deviation.  a Chi-squared test or Student's  t  test.   The peak level of procalcitonin was lower in group A (Figure 1.). The procalcitonin level was below 2 ng/ml for all of the patients in group A, but it increased in 40% of the patients in group B with a peak level higher than 2 ng/ml (P = 0.001). IL-8 level elevation was moderate in group A in contrast to the increase experienced in the control group, which is a well-known characteristic of CPB. The between-group difference in IL-8 was significant after CPB (Figure 2). The same kinetics were found for IL-10 (Table 2). The preoperative concentration of sELAM-1 was higher in group A, and did not increase any further, in contrast to the control group that started at a low preoperative value and subsequently rose significantly (Table 2). The level of soluble ICAM-1 did not show any increase in group A. On the contrary, there was a significant and characteristic increase in the control group. The between-group differences for soluble ICAM-1 were significant after CPB (Figure 3). No significant difference was found in C-reactive protein, IL-6 or IL6r between the groups. The cTr-I levels were lower in group A, especially at the t5 timepoint (Table 2).  Table 2 Results of the inflammatory mediators and cardiac troponin I t1 t2 t3 t4 t5 t6 p C-reactive protein (mg/l) \\u2003Group A 3.7 (1.0–22.6) 79.9 (50.0–131.7) 112.0 (61.1–177.6) <0.001 † \\u2003Group B 2.6 (0.6–10.5) 87.6 (52.4–143.0) 131.0 (71.0–228.0) <0.001 † p  = 0.068* p  = 0.092* p  = 0.168* IL-6 (pg/ml) \\u2003Group A 1.6 (0.4–21.8) 95.0 (13.6–405.1) 46.3 (16.1–149.5) <0.001 † \\u2003Group B 2.0 (0.4–60.6) 130.5 (21.7–353.8) 49.2 (14.8–214.5) <0.001 † p  = 0.107* p  = 0.829* p  = 0.482* IL-6r (ng/ml) \\u2003Group A 43.6 (1.7–125.0) 47.4 (0.7–109.5) 56.2 (25.2–226.3) 0.949 † \\u2003Group B 40.7 (15.6–94.6) 42.4 (22.2–100.5) 50.2 (13.2–104.9) 0.861 † p  = 0.607* p  = 0.914* p  = 0.304* IL-10 (pg/ml) \\u2003Group A 1.9 (0.2–24.0) 47.2 (2.3–476.6) 7.2 (1.3–90.9) <0.001 † \\u2003Group B 2.6 (0.8–9.7) 209.7 (16.3–814.3) 56.1 (3.6–225.1) <0.001 † p  = 0.136* p  = 0.001* p  = 0.001* Soluble endothelial leukocyte adhesion molecule-1 (ng/ml) \\u2003Group A 88.6 (49.8–194.5) 88.5 (14.4–189.6) 72.7 (8.9–163.1) 0.058 † \\u2003Group B 49.0 (18.3–144.1) 130.7 (33.0–360.7) 72.6 (16.7–224.7) <0.001 † p  < 0.001* p  = 0.033* p  = 0.957* Cardiac troponin-I (ng/ml) \\u2003Group A 0.02 (0.01–0.022) 0.22 (0.07–0.85) 0.13 (0.03–0.75) <0.001 † \\u2003Group B 0.01 (0.01–0.016) 0.66 (0.10–1.28) 0.19 (0.03–0.80) <0.001 † p  = 0.520* p  = 0.018* p  = 0.097* Data presented as the median (range). t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  † Intraindividual differences (Friedman test), *between-group differences (Kruskal–Wallis test).   Figure 1Procalcitonin plasma levels before operation and 24 hours after cardiopulmonary bypass. Procalcitonin (PCT) plasma levels in the treated and control groups, before operation (t1) and 24 hours after cardiopulmonary bypass (t5). Significant elevation was found in both groups (*Friedman tests). After the operation, procalcitonin was lower in group A. The between-group difference was significant (+ Kruskal–Wallis test).  Figure 2IL-8 plasma levels before operation and after cardiopulmonary bypass. IL-8 plasma levels in the treated and control groups, before operation (t1) and 10 minutes (t2) and 2 hours (t3) after cardiopulmonary bypass. Significant elevation was found in both groups (*Friedman tests). At t2 and t3 the IL-8 plasma levels were lower in group A. The between-group differences were significant (+Kruskal–Wallis test).  Figure 3Soluble intercellular adhesion molecule 1 plasma levels before operation and after cardiopulmonary bypass. Soluble intercellular adhesion molecule 1 (ICAM-1) plasma levels in the treated and control groups, before operation (t1) and 24 hours (t5) and 44 hours (t6) after cardiopulmonary bypass. No elevation was found in group A, but the elevation was significant in group B (*Friedman tests). The between-group differences were significant after cardiac surgery on cardiopulmonary bypass (+Kruskal–Wallis test).  No difference was found between CABG and AVR patients in the inflammatory markers or cTr-I, except for ICAM-1 in group B, which was higher among AVR patients before operation (p = 0.047) and at the 24-hour timepoint (p = 0.023).  Patients with postoperative atrial fibrillation or pacemaker rhythm in the VVI mode (group A, five patients; group B, four patients) were excluded from the analysis of haemodynamic data. The cardiac index and stroke volume index were higher while the SVRI figures were lower in group A, with an observed statistical power of 83%. The intrathoracic blood volume index, stroke volume variation, heart rate, arterial blood pressure (systolic) (p = 0.787), arterial blood pressure (diastolic) (p = 0.771) and extravascular lung water index (p = 0.326) did not differ between the two groups (Table 3).  Table 3 Results of the haemodynamic data t1 t2 t3 t4 t5 t6 p  value a Heart rate (l/min) 0.925 \\u2003Group A 60 ± 12 76 ± 14 78 ± 13 84 ± 18 84 ± 7 92 ± 10 \\u2003Group B 59 ± 8 72 ± 9 78 ± 12 81 ± 12 87 ± 12 97 ± 12 Stroke volume index (ml/m 2 ) 0.026 \\u2003Group A 38.5 ± 6.5 33.5 ± 9.1 31.9 ± 8.2 32.8 ± 9.0 36.9 ± 13.8 36.1 ± 7.4 \\u2003Group B 36.4 ± 5.7 30.2 ± 5.8 27.6 ± 8.0 27.6 ± 7.5 31.3 ± 10.0 30.1 ± 5.0 Cardiac index (l/min/m 2 ) 0.010 \\u2003Group A 2.3 ± 0.45 2.4 ± 0.39 2.4 ± 0.63 2.7 ± 0.63 3.0 ± 0.98 3.4 ± 0.94 \\u2003Group B 2.2 ± 0.36 2.2 ± 0.31 2.0 ± 0.41 2.2 ± 0.44 2.6 ± 0.38 2.9 ± 0.49 Stroke volume variation (%) 0.873 \\u2003Group A 1.5 ± 0.8 2.3 ± 3.3 3.4 ± 5.3 2.2 ± 1.8 4.5 ± 11.5 2.0 ± 0.7 \\u2003Group B 2.6 ± 3.9 3.1 ± 2.9 4.9 ± 8.5 2.8 ± 3.1 2.5 ± 1.5 2.5 ± 1.0 Intrathoracic blood volume index (ml/m 2 ) 0.387 \\u2003Group A 861 ± 132 829 ± 129 875 ± 120 882 ± 122 923 ± 137 975 ± 136 \\u2003Group B 845 ± 153 811 ± 151 831 ± 192 831 ± 169 871 ± 128 919 ± 214 Systemic vascular resistance index (dyn s/cm 5  m 2 ) 0.005 \\u2003Group A 2,663 ± 414 2,031 ± 492 2,701 ± 604 † 2,418 ± 534 2,076 ± 514 2,052 ± 430 \\u2003Group B 2,732 ± 424 2,279 ± 428 3,499 ± 964 2,902 ± 659 2,470 ± 505 2,227 ± 507 Data presented as the mean ± standard deviation. t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB.  a Between-group differences, general linear model repeated measurement analysis (analysis of variance).  † p  < 0.05 (with Bonferroni adjustment for multiple comparison).BODY.DISCUSSION:For the first time according to the literature, we have shown in the present investigation that dextran-70 reduces the inflammatory cytokine response, reduces the peak levels of serum procalcitonin and reduces the peak levels of the markers of endothelial activation or damage during the inflammatory activation following CPB. Earlier investigation had indicated that dextran-70 reduces complement-3 activation product levels during cardiopulmonary bypass [28], but subsequently it was revealed that fresh frozen plasma, which was applied in the control group in large volume, contains a high level of complement-3 [29].  The exact mechanism of the anti-inflammatory effect of dextran is still unclear. Intravital studies on haemodilution in controlled ischaemia have shown that dextran reduces leukocyte adhesion onto the endothelium. The inhibition of leukocyte–endothelium interaction already occurs in the pharmacological microdose of dextran, independently of the haemodilution effect [8]. On the basis of recently published experimental data, dextran inhibits neutrophil adhesion by a neutrophil-dependent mechanism, regulating integrin function rather than interfering with endothelial cell activation [23]. In the same experimental setting, gelatin represented a similar effect on neutrophil adhesion to that of dextran; therefore, it can be supposed that other mechanisms should also be of importance. The termination of a neutrophil-mediated inflammatory response is effected through apoptosis of the neutrophils. When PMNs were exposed to dextran in whole blood samples, significant apoptosis was demonstrated. By these effects, human PMN survival was found to decrease [30]. Inflammatory mediators also modulate PMN survival. IL-8 plays a major role in the markedly reduced rate of programmed cell death of neutrophils after CPB [31]. In the present investigation we have demonstrated the attenuation of IL-8 release by dextran-70. The free radical scavenger effect of dextran is also well known [8]. This action may contribute to the reduction of endothelial activation and injury after CPB, as clearly demonstrated in our investigation.  From the good predictive value of procalcitonin [6] and its blunted kinetics in the dextran-treated group in our study, one can suppose that dextran-70 may influence the patients' outcome after CPB. Further large-scale studies are required to confirm this assumption.  In our investigation a similarly blunted peak level of IL-8 was found after dextran-70 administration as that reported earlier by Wan and colleagues on coronary patients operated on without CPB [32]. IL-8 plays an important role in the formation of the myocardial and pulmonary ischaemia-reperfusion injury developing after the use of CPB [3,7,33]. Its serum concentration correlates with postoperative cTr-I values [33]. The peak plasma IL-8 level also correlates with the magnitude of the proximal tubular injury following CABG surgery [34]. On the basis of our results, a lower IL-10 peak concentration occurred proportionally with the IL-8 peak level when dextran infusion was used, which indicates that no imbalance developed between proinflammatory and anti-inflammatory responses. High doses of aprotinin or a heparin-coated CPB tubing set also reduce IL-10 production following CPB [33,35]. Steroids increase the concentration of IL-10 with the consequences of immune suppression [35,36].  We found no significant action of dextran-70 on the levels of C-reactive protein, IL-6 and IL-6r, but the peak concentration of IL-6 and C-reactive protein was lower and that of IL-6r was higher in the group administered dextran. Previous investigations proved that IL-6 [33,37] and C-reactive protein [2] levels did not differ in CABG and off-pump coronary artery bypass surgery, but reduced IL-6 levels occurred after minimally invasive direct coronary artery bypass surgery, which suggests that operative trauma itself rather than CPB or ischaemia-reperfusion injury initiates the release of these factors [2]. These results suggest that dextran can reduce the inflammation resulted from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma.  There is an increasing body of evidence that the damaging effect of ischaemia-reperfusion in the heart is related to inflammatory processes [3] and that attenuation of the inflammatory response improves myocardial outcome following cardiac surgery [36]. The pattern of cardiac cTr-I release is similar after CABG and after valve surgery, but off-pump coronary artery bypass surgery results in less elevation than CABG using CPB [38]. Troponin-I release was reduced in the patient group where dextran-70 was applied, which may indicate that dextran-70 decreases the ischaemia-reperfusion injury after cardiac operation. The difference in cTr-I was rather small between the two groups, and therefore its clinical relevance must be confirmed in a large-scale study.  In our investigation dextran infusion has increased the stroke volume index independently of the preload by the reduction of the systemic vascular resistance index. Although the intrathoracic blood volume index and stroke volume variation did not differ between the groups it cannot be excluded that the observed differences in haemodynamics are partly due to the different volume effects of dextran and gelatin – whereas on the basis of our sELAM-1 and soluble ICAM-1 results, dextran infusion reduces the degree of the endothelial damage and activation. Particularly high preoperative sELAM-1 plasma concentration figures were found in the dextran group in contrast to the control group, indicating higher preoperative endothelial dysfunction among these patients. The levels of sELAM-1 and ICAM-1 significantly increased in the control group, but did not change in those patients who received dextran. This effect on the activation and damage of the endothelium may explain dextran's favourable influence on the vasomotor regulatory disturbance. Cardiopulmonary bypass alters vasomotor regulation, reducing the endothelium-dependent relaxation [39]. The nitric oxide production is significantly reduced up to 6 hours after CPB [40], which coincides with the time interval where the main difference in the SVRI was found in our study.  For the statistical analysis, six series of observations were represented over time to show the haemodynamic status at every examined timepoint of the inflammatory mediators. Using Bonferroni correction for multiple comparison, these many timepoints have resulted in a very high correction factor, increasing the possible statistical error, which may mask real differences. Although the observed statistical power was high, particularly in case of the SVRI, the clinical relevance of these finding must be justified in a study investigating a larger population.  The administration of HES 130/0.4 has also been investigated on the inflammatory response in other patient populations (for example, in patients undergoing major abdominal surgery). The IL-6, IL-8 and soluble ICAM-1 release was found to be lower in the HES-treated group, but the concentration of sELAM-1 was similar in the HES-treated and in the lactated Ringer's solution-treated groups [20]. Although HES does possesses anti-inflammatory properties [17,18], as the authors concluded these results were probably due to differences in microcirculation, because crystalloid-based volume therapy may worsen the microcirculatory blood flow and tissue oxygenation despite sufficient haemodynamic conditions [41]. The microhaemodynamic status was not measured in our investigation, but previously gelatin had been shown to increase cerebral blood flow velocity and to improve cutaneous microcirculation, more expressively than HES, during haemodilution (to a haematocrit level of 30.0%). That effect on microcirculation was related inversely to haematocrit, which means that after autologue blood retransfusion the parameters of cutaneous microcirculation have worsened [42]. Similarly to dextran, in our investigation HES was shown to diminish the endothelial activation or damage in critically ill patients. The soluble ICAM-1 and sELAM-1 levels did not increase following HES administration compared with the increase of these molecular levels in the control group treated with human albumin (20%).  On the basis of comparative animal experiments investigating the effects of colloids on leukocyte-endothelial interaction we have investigated the presumably most effective colloid, dextran-70, during CPB and we have proved its anti-inflammatory effect. Having said that, questions still remain of whether dextran has any advantage over other colloids in the anti-inflammatory properties in clinical situations, and whether it results in real clinical benefit on patient outcome. Further clinical studies are required to compare the anti-inflammatory effect of dextran with that of HES, and large-scale clinical studies must justify that the reduction of inflammation by dextran can be translated into clinical benefit. Another question to be raised is whether dextran administrated in a microdose is, or is not, able to reduce the inflammation in clinical situations of systemic inflammatory response syndrome, as in experimental studies [8], because microdose administration eliminates the antihaemostatic effects.  Blood loss was higher in the dextran group than the control group, which can be explained by the higher antihaemostatic potential. This difference, however, is surprisingly not clinically significant, since the number of red blood cell transfusions and haematocrit levels did not differ.  The limitation of this study is that gelatin, or any other colloid, administrated in the control group cannot be considered neutral concerning the inflammatory response. An infusion possessing anti-inflammatory effects is more acceptable for the control group than an infusion with proinflammatory features. Although gelatin administration did not influence neutrophil infiltration, NF-κB activation, proinflammatory cytokines levels, ICAM-1 mRNA expression and myeloperoxidase activity in a septic model [17], a moderate favourable effect on inflammation was indicated, reducing the Ba fragment of the complement cascade [24] and impairing the firm leukocyte adhesion in an in vitro model [23]. Certain albumin batches possess well-documented proinflammatory actions (for example, activating E-selectin, ICAM-1, vascular cell adhesion molecule 1), which seriously question the relevance of human albumin as a valid control for studies concerning inflammation [43]. Also, the use of lactated Ringer infusion is associated with significant neutrophil activation [44] and early expression of endothelial E-selectin and P-selectin [45]. Another limitation of this study is the single institutional setting. There were no differences in morbidity, mortality or length of intensive care unit stay between the groups but the low number of patients in our study does not allow one to conclude on the clinical outcome parameters.BODY.CONCLUSION:To the best of our knowledge our investigation is the first to show that dextran-70 reduces the inflammatory cytokine response, the liberation of some soluble adhesion molecules and the peak level of procalcitonin following cardiac operations. These results suggest that dextran can reduce the inflammation resulting from either the use of CPB or ischaemia-reperfusion injury rather than from operative trauma. Further large-scale clinical studies are required to demonstrate this effect on patient outcome after cardiac surgery.BODY.KEY MESSAGES:• Dextran-70 reduces the inflammatory activation after CPB.BODY.ABBREVIATIONS:AVR = aortic valve replacement; CABG = coronary artery bypass grafting; CPB = cardiac surgery on cardiopulmonary bypass; cTr-I = cardiac troponin I; ELISA = enzyme-linked immunosorbent assay; HES = hydroxyethyl starches; ICAM-1 = intercellular adhesion molecule-1; IL = interleukin; NF = nuclear factor; PMN = polymorphonuclear leukocyte; sELAM-1 = soluble endothelial leukocyte adhesion molecule-1; SVRI = systemic vascular resistance index; TNF = tumour necrosis factor.BODY.COMPETING INTERESTS:The authors declare that they have no competing interests.BODY.AUTHORS' CONTRIBUTIONS:KG conceived the study, participated in the design, coordination, measurements and acquisition of data, performed the statistical analysis, drafted the manuscript and obtained sponsorship. AB made a substantial contribution to the execution of the study and acquisition of data. NA and LB made a substantial contribution to the design of the study, interpretation of the data and provided critical review of the manuscript. NA participated in the coordination of the study. GK participated in the study design and helped to write the manuscript. VG and JG carried out the immunoassays, discussed the results and provided a critical review of the manuscript. TK carried out laboratory measurements, discussed the results and provided a critical review of the manuscript. All authors read and approved the final manuscript.\", 'TITLE: Hyperbaric Oxygen Therapy Facilitates Healing of Chronic Foot Ulcers in Patients With DiabetesABSTRACT.OBJECTIVE:Chronic diabetic foot ulcers are a source of major concern for both patients and health care systems. The aim of this study was to evaluate the effect of hyperbaric oxygen therapy (HBOT) in the management of chronic diabetic foot ulcers.ABSTRACT.RESEARCH DESIGN AND METHODS:The Hyperbaric Oxygen Therapy in Diabetics with Chronic Foot Ulcers (HODFU) study was a randomized, single-center, double-blinded, placebo-controlled clinical trial. The outcomes for the group receiving HBOT were compared with those of the group receiving treatment with hyperbaric air. Treatments were given in a multi-place hyperbaric chamber for 85-min daily (session duration 95 min), five days a week for eight weeks (40 treatment sessions). The study was performed in an ambulatory setting.ABSTRACT.RESULTS:Ninety-four patients with Wagner grade 2, 3, or 4 ulcers, which had been present for >3 months, were studied. In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03). In a sub-analysis of those patients completing >35 HBOT sessions, healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009). The frequency of adverse events was low.ABSTRACT.CONCLUSIONS:The HODFU study showed that adjunctive treatment with HBOT facilitates healing of chronic foot ulcers in selected patients with diabetes.BODY:Diabetic foot ulcers are a common and serious complication of diabetes (1,2). Treatment often requires long-term hospital admissions and frequent outpatient visits. Furthermore, loss of mobility poses a great burden on the patient and the health care system (3). At centers of excellence, 19–35% of ulcers are reported as nonhealing (4–6). Thus, despite improvements in healing diabetic foot ulcers, there is still a need for new treatment strategies and methods.  Systemic hyperbaric oxygen therapy (HBOT) has been proposed as a medical treatment for diabetic foot ulcers (7). HBOT has been demonstrated to have an antimicrobial effect and to increase oxygenation of hypoxic wound tissues (8–10). This enhances neutrophil killing ability, stimulates angiogenesis, and enhances fibroblast activity and collagen synthesis (9,11,12). Thus, theoretically, HBOT could improve the healing of ischemic foot ulcers in patients with diabetes. HBOT has been advocated and adopted by a number of centers even though the evidence of its effectiveness is limited (13–16). The first published double-blinded, randomized, controlled trial by Abidia et al. (17) in 2003 suggested the benefit of HBOT, but the study was small and included only patients with Wagner grade 1 and 2 ulcers. Therefore, the clinical utility of HBOT in treating diabetic foot ulcers was not established. The final conclusion of an analysis completed in 2004 by the Cochrane Collaboration found that further research was needed and the need for larger randomized placebo-controlled studies was highlighted (13).  The aim of the Hyperbaric Oxygen Treatment in Diabetic Patients with Chronic Foot Ulcers (HODFU) study was to evaluate if adjunctive treatment with HBOT, when compared with treatment with hyperbaric air (placebo), would have any therapeutic effect on chronic foot ulcers in patients with diabetes.BODY.RESEARCH DESIGN AND METHODS:This study was initiated, designed, and performed by the authors. A steering committee was in charge of organization, data handling, and general conduct of the study. A blinded clinical event committee evaluated and classified all reported events as well as clinical outcome. The protocol was approved by the ethics committee at the Lund University.  The HODFU study was a randomized, single-center, double-blinded, placebo-controlled clinical trial that evaluated the effect of HBOT on ulcer healing in patients with diabetes and chronic foot ulcers. The outcomes for the group receiving HBOT were compared with those of the group receiving treatment with hyperbaric air. The study design and rationale were reported in detail previously (18).  All patients had diabetes and at least one full-thickness wound below the ankle for >3 months. They were previously treated at a diabetes foot clinic for a period of no <2 months. All patients were assessed by a vascular surgeon at the time of inclusion and only patients with adequate distal perfusion or nonreconstructable peripheral vascular disease were included in the study. Patients having an acute foot infection were included when the acute phase was resolved. Oral or local antibiotic treatment did not exclude patients from study participation. Exclusion criteria for study participation were contraindications for hyperbaric treatment (severe obstructive pulmonary disease, malignancy, and untreated thyrotoxicosis), current drug or alcohol misuse, vascular surgery in the lower limbs within the last two months, participation in another study, or suspected poor compliance. All participants provided written informed consent.BODY.RESEARCH DESIGN AND METHODS.PROCEDURES:Patients were stratified based upon arterial toe blood pressure (≤35 mmHg vs. >35 mmHg) before being randomly assigned to either of the treatment arms. Randomization was done in blocks of 10 using sealed envelopes.  The study was performed in an ambulatory setting. Treatment sessions were given in a multi-place hyperbaric chamber five days per week for eight weeks (40 treatment sessions). The treatment period could be extended to 10 weeks, but the number of treatments was not allowed to exceed 40. An HBOT session included a period of compression in air for 5 min, followed by a treatment period at 2.5 atmospheres absolute (ATA) for 85 min, and then a decompression period of 5 min. Patients from both groups could be treated in the same session as study gases were administered by masks and air or 100% oxygen entered the chamber through separate double-blinded pipes (19). Study treatment was given as an adjunct to regular treatment at the multidisciplinary diabetes foot clinic, which included treatment of infection, revascularization, debridement, off-loading, and metabolic control according to high international standards (18). Investigators did not intervene in the daily routine clinical management of the patients. Outcomes were measured every first week during the treatment period (first 8–10 weeks) and then at three-month intervals. Ulcers were graded using the Wagner classification system and ulcer areas were measured using Visitrak Digital (Smith & Nephew, Hull, England) (20).BODY.RESEARCH DESIGN AND METHODS.END POINTS:The primary end point was healing of the index ulcer. The index ulcer was defined as the ulcer with the largest area and a duration of at least three months at the time of inclusion. An ulcer was considered healed when it was completely covered by epithelial regeneration and remained so until the next visit in the study. Wagner grade 4 ulcers were considered healed when the gangrene had separated and the ulcer below was completely covered by epithelial regeneration. If a patient died during the follow-up period, he/she was censored at the time of the death. If a major amputation (above ankle amputation) was required, the ulcer was considered not to have healed. Secondary end points reported in this paper are major amputations and death.BODY.RESEARCH DESIGN AND METHODS.STATISTICAL ANALYSIS:The treatment code was not broken until the last patient had completed the 1-year follow-up visit.  Statistical evaluation was initially performed as an intention-to-treat analysis. An analysis was also performed on those patients who received >35 treatments (per protocol analysis). Categorical variables were analyzed using contingency tables (Fisher exact test) and continuous variables using Mann-Whitney U test. A two-sided P value <0.05 was considered statistically significant. Statistical analysis was performed using Statistica software, version 8.0 (Statsoft, Tulsa, OK).BODY.RESULTS.ENROLLMENT AND BASAL CHARACTERISTICS OF THE PATIENTS:During the inclusion period, a total of 164 eligible participants were registered: 23 (14%) did not consent to participation, 47 (29%) were excluded according to the study protocol, and 94 (57%) underwent randomization (Fig. 1).  Figure 1Study flow chart of the HODFU study. COPD, chronic obstructive pulmonary disease.  The two groups had similar characteristics at baseline (Table 1). The median ulcer duration was 10 months and the median ulcer area was 3 cm2. A majority of index ulcers were classified as Wagner grade 3 and 4 (20). Vascular surgery was previously performed in the affected lower limb in 55% of the participants.   Table 1 Basal patient characteristics at randomization. Lower extremity data are given only for index ulcer limb. Categorical variables are given as percent and continuous variables as medians and ranges HBOT Placebo Number of patients 49 45 Age (years) 69 (37–95) 68 (28–86) n.s. Females (%) 22 16 n.s. Smoking habits 61 69 n.s. \\u2003\\u2003\\u2003\\u2003Current (%) 22 29 n.s. \\u2003\\u2003\\u2003\\u2003Previous (%) 41 38 n.s. \\u2003\\u2003\\u2003\\u2003Pack-years (nonsmokers excluded) 26 (1–47) 25 (4–73) n.s. Mobility \\u2003\\u2003\\u2003\\u2003Walking without support (%) 43 44 n.s. \\u2003\\u2003\\u2003\\u2003Walking with support (%) 38 31 n.s. \\u2003\\u2003\\u2003\\u2003Wheelchair (%) 18 24 n.s. Diabetes duration (years) 20 (1–63) 23 (3–54) n.s. Diabetes type 1/2 (%) 24/76 42/58 n.s. Glycated hemoglobin (%) * 7.8 (4.2–11.0) 8.1 (5.0–12.5) n.s. Hemoglobin (g/l) 127 (95–156) 123 (95–160) n.s. Creatinine (μmol/l) 104 (52–804) 101 (48–687) n.s. C-reactive protein (mg/l) 8 (1–161) 7 (1–49) n.s. Leukocyte count (10 9 /l) 8.5 (3.7–13.1) 7.7 (1.9–13.8) n.s. Concomitant diagnoses \\u2003\\u2003\\u2003\\u2003Hypertension (%) 76 73 n.s. \\u2003\\u2003\\u2003\\u2003Hyperlipidemia (%) 88 87 n.s. \\u2003\\u2003\\u2003\\u2003Myocardial infarction (%) 25 33 n.s. \\u2003\\u2003\\u2003\\u2003Stroke (%) 16 16 n.s. \\u2003\\u2003\\u2003\\u2003Congestive heart failure (%) 35 27 n.s. \\u2003\\u2003\\u2003\\u2003Atrial fibrillation (%) 25 33 n.s. \\u2003\\u2003\\u2003\\u2003Nephropathy (%) 90 80 n.s. \\u2003\\u2003\\u2003\\u2003Dialysis (%) 6 7 n.s. \\u2003\\u2003\\u2003\\u2003Renal transplant (%) 4 2 n.s. \\u2003\\u2003\\u2003\\u2003Prior major amputation †  (%) 14 7 n.s. \\u2003\\u2003\\u2003\\u2003Prior minor amputation (%) 32 47 n.s. \\u2003\\u2003\\u2003\\u2003Charcot foot (%) 4 9 n.s. Medication \\u2003\\u2003\\u2003\\u2003Insulin (%) 90 91 n.s. \\u2003\\u2003\\u2003\\u2003Metformin (%) 10 13 n.s. \\u2003\\u2003\\u2003\\u2003Sulfonylurea (%) 12 16 n.s. \\u2003\\u2003\\u2003\\u2003Statin (%) 69 60 n.s. \\u2003\\u2003\\u2003\\u2003Aspirin (%) 63 56 n.s. \\u2003\\u2003\\u2003\\u2003Clopidrogel (%) 8 13 n.s. \\u2003\\u2003\\u2003\\u2003Warfarin (%) 18 24 n.s. \\u2003\\u2003\\u2003\\u2003ACE-inhibitor or ARB ‡  (%) 69 74 n.s. \\u2003\\u2003\\u2003\\u2003β-blocker (%) 39 40 n.s. \\u2003\\u2003\\u2003\\u2003Diuretics (%) 67 51 n.s. \\u2003\\u2003\\u2003\\u2003Antibiotics, oral (%) 65 73 n.s. \\u2003\\u2003\\u2003\\u2003Antibiotics, intravenous (%) 0 0 n.s. Index ulcer size (cm 2 ) 3.1 (0.6–55) 2.8 (0.6–39) n.s. Ulcer duration (months) 9 (3–44) 10 (3–39) n.s. Wagner classification \\u2003\\u2003\\u2003\\u2003Grade 1 (%) 0 0 n.s. \\u2003\\u2003\\u2003\\u2003Grade 2 (%) 24 27 n.s. \\u2003\\u2003\\u2003\\u2003Grade 3 (%) 51 62 n.s. \\u2003\\u2003\\u2003\\u2003Grade 4 (%) 24 11 n.s. \\u2003\\u2003\\u2003\\u2003Grade 5 (%) 0 0 n.s. Index ulcer location \\u2003\\u2003\\u2003\\u2003Toe (%) 35 47 n.s. \\u2003\\u2003\\u2003\\u2003Plantar forefoot (%) 27 24 n.s. \\u2003\\u2003\\u2003\\u2003Middle foot (%) 14 13 n.s. \\u2003\\u2003\\u2003\\u2003Heel (%) 16 7 n.s. \\u2003\\u2003\\u2003\\u2003Malleoli (%) 6 7 n.s. \\u2003\\u2003\\u2003\\u2003Dorsal (%) 2 0 n.s. Peripheral circulation \\u2003\\u2003\\u2003\\u2003Previous vascular surgery (%) 57 49 n.s. \\u2003\\u2003\\u2003\\u2003Toe blood pressure (mmHg) 50 (5–130) 55 (15–160) n.s. \\u2003\\u2003\\u2003\\u2003Toe blood pressure ≤60 mmHg (%) 57 57 n.s. \\u2003\\u2003\\u2003\\u2003Toe blood pressure ≤35 mmHg (%) 33 29 n.s. *Glycated hemoglobin recalculated to % in Diabetes Control and Complications Trial standard, †above ankle amputation, ‡angiotensin II receptor blocker. n.s., not significant.BODY.RESULTS.TREATMENT:Fifty-four (57%) patients completed all 40 treatment sessions, and 75 (80%) completed >35 sessions. Nine patients completed <10 treatment sessions, and the remaining 10 patients completed between 14 and 28 sessions. Early treatment termination was due to claustrophobia in two patients and worsening medical condition in nine patients (two deaths, two major amputations, and five hospitalizations). Eight patients decided to withdraw from the study.  Open vascular surgery in the affected lower limb was not performed on any study participant during the 1st year after inclusion, whereas percutaneous transluminal angioplasty (PTA) was carried out in 10 patients (Table 2).   Table 2 PTA was performed in 10 patients during the first year of follow-up. Baseline arterial toe blood pressure, number of treatment sessions given, and ulcer outcome are specified for those patients PTA intervention (months after randomization) Total number of HBOT treatments Arterial toe blood pressure at inclusion Outcome of index ulcer Amputation HBOT Group \\u2003\\u2003\\u2003\\u20033 40 15 mmHg Unhealed Above ankle amputation at 7 months \\u2003\\u2003\\u2003\\u20036 40 25 mmHg Healed at 6 months Toe amputation at 8 months \\u2003\\u2003\\u2003\\u20037 38 20 mmHg Unhealed Toe amputation at 10 months \\u2003\\u2003\\u2003\\u20037 40 30 mmHg Healed at 3 months No \\u2003\\u2003\\u2003\\u20037 38 40 mmHg Healed at 12 months No \\u2003\\u2003\\u2003\\u20038 40 20 mmHg Unhealed No Placebo Group \\u2003\\u2003\\u2003\\u20032 40 20 mmHg Unhealed No \\u2003\\u2003\\u2003\\u20033 37 45 mmHg Unhealed No \\u2003\\u2003\\u2003\\u20036 38 50 mmHg Unhealed No \\u2003\\u2003\\u2003\\u20037 38 25 mmHg Healed at 9 months NoBODY.RESULTS.EFFECT ON ULCER HEALING:In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03). In the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009) (Fig. 2). The largest differences in healing rates between groups were seen at the nine-month follow-up. Numbers needed to treat to avert nonhealing of a chronic foot ulcer were 4.2 and 3.1 according to the intention-to-treat and per-protocol analysis, respectively. During the 1st-year of follow-up, new ulcers developed in nine patients in the HBOT group and eight patients in the control group.  Figure 2Healing rates in patients given treatment with hyperbaric oxygen therapy (HBOT) as compared with hyperbaric air (placebo). *P < 0.05; **P < 0.01.BODY.RESULTS.EFFECTS ON AMPUTATION AND DEATH:Four participants—one in the HBOT group and three in the placebo group—died during their 1st year in the study. The patient in the HBOT group received eight treatments and died of multiple organ failure 20 days after inclusion. She was 87-years-old and had a medical history including severe peripheral artery disease, neuropathy, myocardial infarction, and heart failure. In the placebo group, the causes of death were myocardial infarction in two patients (at 162 days after 39 treatments and 218 days after 22 treatments) and sepsis derived from an infected foot ulcer in one patient (at 144 days after 40 treatments).  Three major amputations were performed in the HBOT group as compared with one in the placebo group within the 1st year. In the HBOT group, two of the three amputations were done within 2 months after inclusion and the third was done at 191 days. The amputation in the placebo group was performed 98 days after inclusion. All four patients had an arterial toe blood pressure ≤15 mmHg in the affected lower limb. Two of these ulcers were classified as Wagner grade 4 and two were classified as grade 3 ulcers (20). Four minor amputations were performed in each group during the 1st year of follow-up.BODY.RESULTS.ADVERSE REACTIONS:All together 3,225 treatment sessions were given in the HODFU study. As discussed above, one fatal outcome was seen in the HBOT group during the treatment period, and a relation between HBOT and this fatal outcome cannot be excluded. In the placebo group, one patient was hospitalized for 24 h after temporarily losing consciousness after a treatment session.  Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.). One of the patients in the HBOT group was hospitalized due to the event.  One patient in the HBOT group endured barotraumatic otitis. Another four patients, two in each group, required myringotomy with tube placement due to pain caused by the inability to equilibrate air pressure through the eustachian tube.  In the HBOT group, treatment-related dizziness was seen in one patient and the worsening of cataracts in another. One case of minor head injury occurred in the placebo group after a fall inside the hyperbaric chamber. Oxygen toxicity, seizures, or pneumothorax were not seen.BODY.CONCLUSIONS:The present study supports the concept that adjunctive treatment with HBOT enhances foot ulcer healing in selected patients with diabetes. Accordingly, in our patients with long-standing chronic ulcers at 1-year follow-up, HBOT doubled the number of healed ulcers as compared with adjunctive treatment with hyperbaric air used as placebo.  In this study, arterial toe blood pressure was not a discriminating factor for beneficial effect of HBOT (data not shown). Patients with arterial toe blood pressure as low as 5 mmHg did heal in the HBOT group, and we could not identify a lower level of arterial toe blood pressure for nonhealing. Ulcer healing rate in the placebo group might be lower than expected, probably mainly reflecting a long prestudy period of failure to heal.  Our findings are in agreement with those reported in previous randomized studies focused on ulcer healing by Abidia et al. (17), Duzgun et al. (21), Kessler et al.(22), and Kalani et al. (23). Abidia et al. evaluated the effect of HBOT compared with hyperbaric air in a double-blind study of ischemic Wagner grade 1 and 2 ulcers. In that study of 18 patients, a nonsignificant improvement of healing rate following HBOT was seen after six weeks, which reached statistical significance at 1-year follow-up. In the unblinded, randomized study by Duzgun et al., the effect of HBOT was compared with standard therapy in 100 patients with a foot ulcer duration of at least four weeks. During a mean follow-up period of 92 weeks, primary healing was achieved in 66% of patients receiving HBOT compared with 0% following standard therapy (21). In the randomized trial by Kessler et al., the effect of two daily 90-min sessions of HBOT five days a week for two weeks was compared with regular treatment in 28 hospitalized patients with neuropathic Wagner grade 1 to 3 ulcers (22). After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037). However, this improvement disappeared during the next two weeks of follow-up. The study by Kalani et al. included 38 patients with ischemic ulcers without full-thickness gangrene. After three years, 76% of the 17 patients receiving HBOT had healed their ulcers to intact skin compared with 48% of those given conventional treatment. However, these data should be interpreted with caution as the randomization procedure was not sustained through the study (23).  In contrast to our findings, some studies have shown the beneficial effect of HBOT in preventing amputations (8,21,23). Our study had insufficient power to analyze the rate of major amputations, which were only performed due to life-threatening infection and refractory pain. In the studies by Faglia et al. (8), Kalani et al. (23), and Duzgun et al. (21), amputation rates were substantially higher than in our study, suggesting these studies used other indications for major amputation (i.e., long-term unhealed ulcers) (8,21,23). This might indirectly be mirrored in toe blood pressure levels that were ≤15 mmHg in our amputated patients compared with 42 ± 30 mmHg in the study by Kalani et al. (23). Also, a possible bias effect cannot be excluded in open studies where the investigator may be involved in the decision to amputate.  Although >50% of our patients had had at least one previous vascular intervention at the time of randomization and the need for—or possibility of—vascular surgical intervention had been excluded at time of inclusion, PTA was performed in 10 patients (11%) within one year of randomization. This partly reflects a general problem in evaluating the effects of different treatment methods for diabetic foot ulcers and is not unique for our study. For instance in the study by Faglia et al. (8), vascular surgical intervention was performed in 38% of the patients during the follow-up period. The implications of these interventions on study outcome have been debated (24). In our study, however, PTA intervention cannot explain the higher ulcer healing rate in the HBOT group as only three ulcers, one of which was in the placebo group, healed following PTA.  The frequency (6%) of middle ear barotrauma or the need for myringotomy with tube placement was not higher in our study population of relatively old patients with severe cardiovascular disease and neuropathy compared with previously reported data in younger patients (25). In our treatment schedule, an HBOT session included a period of compression in air for 5 min, followed by a treatment period at 2.5 ATA for 85 min, and then a decompression period of 5 min. This schedule has been shown to be safe for scuba divers and our study showed it to be safe in our diabetic foot ulcer population where 3,225 treatments were given without decompression sickness, seizures, or pneumothorax.  In conclusion, the HODFU study, a double-blinded, randomized, placebo-controlled trial, showed that adjunctive treatment with HBOT facilitates healing of chronic foot ulcers in selected patients with diabetes.']\n"
     ]
    }
   ],
   "source": [
    "\"\"\" Read article by name \"\"\"\n",
    "def read_article(id) -> str:\n",
    "    with open(TAR_PATH+look_up[id], 'r', encoding='utf-8') as f:\n",
    "        return f.readlines()[0]\n",
    "\n",
    "text_left = [read_article(id) for id in annot['PMCID']]\n",
    "# print(text_left[0:5])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id_left</th>\n",
       "      <th>text_left</th>\n",
       "      <th>id_right</th>\n",
       "      <th>text_right</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4868208</td>\n",
       "      <td>TITLE: Effects of Kinesio taping and Mcconnell...</td>\n",
       "      <td>9144</td>\n",
       "      <td>Statistically significant between-group\\r\\r\\r\\...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>5384512</td>\n",
       "      <td>TITLE: Bremelanotide for Female Sexual Dysfunc...</td>\n",
       "      <td>6597</td>\n",
       "      <td>For 1.25/1.75-mg pooled versus placebo, mean c...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>5729670</td>\n",
       "      <td>TITLE: Comparison of Two Protocols in the Mana...</td>\n",
       "      <td>10698</td>\n",
       "      <td>The parameters for glycemic variability (SD of...</td>\n",
       "      <td>-1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3479017</td>\n",
       "      <td>TITLE: The effect of a comprehensive lifestyle...</td>\n",
       "      <td>7291</td>\n",
       "      <td>&lt;td align=\"left\" valign=\"bottom\"&gt;Average veget...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5168897</td>\n",
       "      <td>TITLE: Comparative randomised study of GlideSc...</td>\n",
       "      <td>6272</td>\n",
       "      <td>We detected three cases of sore throat in each...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>1868022</td>\n",
       "      <td>TITLE: Papanicolaou smears and cervical inflam...</td>\n",
       "      <td>6424</td>\n",
       "      <td>CVL levels of IL-8, IL-1β and IL-6 remained un...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>5673730</td>\n",
       "      <td>TITLE: Feto-maternal outcomes and Glycemic con...</td>\n",
       "      <td>1338</td>\n",
       "      <td>here was more number of cesarean sections due ...</td>\n",
       "      <td>-1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>5571493</td>\n",
       "      <td>TITLE: Glycemic effects of quinine infusion in...</td>\n",
       "      <td>10309</td>\n",
       "      <td>There were no signs of hypoglycemia or signifi...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>3529678</td>\n",
       "      <td>TITLE: CanPrevent: a telephone-delivered inter...</td>\n",
       "      <td>3749</td>\n",
       "      <td>&lt;td align=\"left\" valign=\"bottom\"&gt; Vegetables, ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>4318496</td>\n",
       "      <td>TITLE: Video game training and the reward syst...</td>\n",
       "      <td>10041</td>\n",
       "      <td>Interestingly, when using uncorrected signific...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   id_left                                          text_left  id_right  \\\n",
       "0  4868208  TITLE: Effects of Kinesio taping and Mcconnell...      9144   \n",
       "1  5384512  TITLE: Bremelanotide for Female Sexual Dysfunc...      6597   \n",
       "2  5729670  TITLE: Comparison of Two Protocols in the Mana...     10698   \n",
       "3  3479017  TITLE: The effect of a comprehensive lifestyle...      7291   \n",
       "4  5168897  TITLE: Comparative randomised study of GlideSc...      6272   \n",
       "5  1868022  TITLE: Papanicolaou smears and cervical inflam...      6424   \n",
       "6  5673730  TITLE: Feto-maternal outcomes and Glycemic con...      1338   \n",
       "7  5571493  TITLE: Glycemic effects of quinine infusion in...     10309   \n",
       "8  3529678  TITLE: CanPrevent: a telephone-delivered inter...      3749   \n",
       "9  4318496  TITLE: Video game training and the reward syst...     10041   \n",
       "\n",
       "                                          text_right  label  \n",
       "0  Statistically significant between-group\\r\\r\\r\\...      1  \n",
       "1  For 1.25/1.75-mg pooled versus placebo, mean c...      1  \n",
       "2  The parameters for glycemic variability (SD of...     -1  \n",
       "3  <td align=\"left\" valign=\"bottom\">Average veget...      0  \n",
       "4  We detected three cases of sore throat in each...      0  \n",
       "5  CVL levels of IL-8, IL-1β and IL-6 remained un...      0  \n",
       "6  here was more number of cesarean sections due ...     -1  \n",
       "7  There were no signs of hypoglycemia or signifi...      0  \n",
       "8  <td align=\"left\" valign=\"bottom\"> Vegetables, ...      1  \n",
       "9  Interestingly, when using uncorrected signific...      1  "
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.DataFrame(data={\n",
    "    'id_left': annot['PMCID'],\n",
    "    'text_left': text_left,\n",
    "    'id_right': annot['PromptID'],\n",
    "    'text_right': annot['Annotations'],\n",
    "    'label': annot['Label Code']\n",
    "})\n",
    "\n",
    "\"\"\" Split data pack into train/valid \"\"\"\n",
    "train, valid = train_test_split(df, test_size=0.2)\n",
    "train_pack = mz.pack(train, task=TYPE)\n",
    "valid_pack = mz.pack(valid, task=TYPE)\n",
    "train_pack.frame().head(10) # DataFrame"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'matchzoo.data_pack.data_pack.DataPack.FrameView'>\n",
      "['id_left', 'text_left', 'id_right', 'text_right', 'label']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dp = mz.pack(df, task=TYPE)\n",
    "print(type(dp.frame))\n",
    "frame_slice = dp.frame[0:5]\n",
    "print(list(frame_slice.columns))\n",
    "full_frame = dp.frame()\n",
    "len(full_frame) == len(dp)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Train "
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
